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Abstract 
This study examined the relationships between sex hormones (serum 
concentrations and urinary excretion of testosterone and estradiol) and serum lipid, 
lipoprotein-lipid and apolipoprotein concentrations in healthy Chinese men. The results 
showed a number of statistically significant associations: The urinary unconjugated 
estradiol excretion was directly, but weakly, associated with serum concentrations of 
HDL3-C (r=0.3073, p=0.038). When expressed as a percentage of the total estradiol 
excretion this association increased in strength (r=0.401, p=0.0058). Total urinary 
estradiol excretion was weakly and inversely associated with serum total cholesterol 
concentration (r=-0.3102, p=0.0359), and LDL-C ( r=-0.307, p=0.0379) and more 
strongly with apolipoprotein B (r=-0.379, p=0.0094). However, neither urinary 
unconjugated nor total testosterone excretions were associated with any lipoprotein-
lipids in serum univariately. Similarly urinary free Cortisol showed no significant 
associations with any lipoprotein variable. 
On stepwise multiple regression which included all the sex hormone variables 
the association between unconjugated estradiol and HDL3-C became stronger (t=2.8, 
p=0.0076) and the association with apolipoprotein B became significant (t=2.32, 
p=0.025). Similarly the associations between total estradiol excretion and total 
cholesterol, LDL-C, and apolipoprotein B became significantly stronger (t=-2.6, 
p=0.0126; t=-2.53, p=0.0153; t=-3.06, p=0.0038, respectively), and a weak 
association with HDL3-C developed (t=-2.05, p=0.0468). 
When triglyceride concentration was included in the model (the metabolism of 
triglyceride is known to be closely linked with that of high density lipoprotein and its 
subfractions) the following associations were found: Urinary estradiol was not 
associated with HDL-C and HDL2-C, but was with HDL3-C. However, HDL-C and 
HDL2-C remained directly associated with serum testosterone (total and/or unbound) in 
i 
this model. ApoA-I, independently of triglyceride, correlated directly and significantly 
(p= 0.02) with SHBG after multiple linear regression with all possible confounding 
variables. 
The results of this study are consistent with the observation that pre-menopausal 
women have lower serum concentrations of the atherogenic lipoproteins LDL-C and 
apoB. Pre-menopausal women are at lower risk for the development of coronary artery 
disease. However other reports have suggested that men with CAD actually have 
higher estrogen levels than men without disease, implying that any beneficial effect on 
lipoproteins in men from higher estrogen levels provides no protection. The existence 
of correlations is not proof of metabolic cause and effect. Further studies in this area 
should be pursued because this might be helpful in the elucidation of the relation 
between sex hormone secretion in normal and abnormal lipid status. 
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Chapter I. Introduction 
Based on a single biological sample, the associations between serum sex 
hormone and lipoprotein concentrations have shown many discrepancies (Heller, 
et al 1983; Semmens et al, 1983; Stefanick et al” 1987; Kiel, et al 1989). 
Since the plasma hormone levels reflect episodic and diurnal variations, 
associations may be obscured. In this study an attempt was made to reduce such 
variation by measuring serum concentrations on two occasions about 2-3 weeks 
apart. Furthermore, on the basis that the 24-hr urinary excretion of sex 
hormones is likely to be independent of short term fluctuations in plasma 
hormone levels and that no study to date has examined the relationship of the 
concentrations of serum lipoprotein-lipids to the excretion of urinary sex 
hormones, urinary sex hormone excretion in addition to analysis of sex hormones 
in plasma was determined. In this project, sampling of blood and 24-hr urine 
collections on two different occasions, 2-3 weeks apart, were used to estimate 
and account for the biological variation. In addition, to reduce another source of 
variation, biochemical assays were done in duplicate because analytical variation 
as well as intra-individual variation will contribute to the overall variation. 
Four considerations need to be noted: 
1. Urinary conjugated testosterone in men is not uniquely a metabolite of plasma 
secreted testosterone. This is based on the finding of Camacho & Migeon (1964) 
and Korenman and Lipsett (1964)，who showed a substantial amount of adrenal 
androgens (mainly androstenedione) are transformed, metabolized and excreted as 
testosterone glucuronide in urine. 
2. Urinary un-conjugated (extractable) testosterone in men mostly originates from 
gonadal secretion rather than from exogenous testosterone or from peripheral 
transformation. This is based on the finding of Camacho & Migeon (1964) that 
after the injection of radiolabelled testosterone and other closely related steroids 
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(such as 17-a hydroxyprogesterone, androstenedione and DHEA) into normal 
men only a very insignificant amount (from 0 to 0.007%) of the injected dose of 
radiolabelled testosterone is recovered in the ether extracted fraction of crude 
urine, while the conjugated fractions of the testosterone account for practically all 
of the radioactivity recovered. 
3. In animal studies measurements of urinary un-conjugated steroids are reliable 
indices of the secretory activity of the adrenal-gonadal axis after hCG 
administration (Fenske, 1988; 1989). 
4. Most of the plasma testosteone in men is secreted by the gonads (Lipsett et 
al” 1968). 
In 1980，Masarei's group in Australia was one of the first to ask the 
question "to what extent does variation in endogenous sex hormone levels 
contribute to variation in serum lipoprotein concentration?" They documented 
that plasma estradiol concentrations show a weak positive correlation with HDL-
C, while plasma sex hormone-binding globulin (SHBG) levels are strongly 
correlated with HDL-C in both post- and pre-menopausal women. In 1983, 
subsequent studies performed by the same group showed a direct association 
between total testosterone and HDL-C but this became an inverse association on 
controlling for SHBG suggesting that there is an inverse correlation between 
unbound endogenous testosterone and HDL-C. They showed a direct correlation 
between SHBG and HDL-C in men and women. The work of Goldberg and his 
co-workers (1985) supported the findings of Masarei's group by suppression of 
plasma testosterone by a long-acting gonadotropin releasing hormone analog 
( L H R H a ) in normal men, which leads to an increase in serum total and high 
density lipoprotein cholesterol and apolipoprotein A-I and B. Stefanick and co-
workers (1987) showed that the plasma total testosterone levels had significant 
inverse associations with HDL cholesterol and HDL〗 mass concentrations, and a 
10 
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significant negative relationship was found between SHBG and triglycerides. 
Nevertheless, the data of other workers pursuing this subject showed a 
different result by suggesting a direct relationship of HDL-C and unbound 
testosterone in men. Among these, the work of Heller and his co-workers 
(1983)，which appeared almost at the same time as the paper by Masarei's 
group (Semmens et al” 1983) is a good example, although salivary testosterone 
was used as an index of free hormone levels. Kiel et al (1989) presented a 
negative result showing that there is no association between total- or free-
testosterone and HDL-C, whereas there is a consistently positive correlation 
between total estradiol or calculated free estradiol and both total cholesterol and 
HDL-C. In addition, they documented a complex interaction between 
endogenous testosterone and estradiol in relation to the lipoprotein profile. The 
above results, though not consistent, all suggest that sex hormones exert an 
important effect on lipoprotein metabolism and play a key role in defining the 
lipoprotein profile in men. 
In view of the controversial results of the previous studies, it was decided 
to re-assess the problem by studying not only serum sex hormone levels and the 
concentrations of lipoprotein-lipids and apolipoproteins in human male subjects 
(not in women because of the additional problem of cyclical changes) but also the 
urinary excretion rate as a reflection of production and secretion of sex 
hormones. 
Nanjee and Miller (1989) reported that plasma Cortisol level, independent 
of plasma level of triglyceride, HDL-C and androstenedione, is positively 
correlated with plasma low density lipoprotein cholesterol (LDL-C) concentration 
in men. As there is considerably diurnal and time-to-time variation in plasmal 
Cortisol levels, which would turn to obscure any association, it is interesting to 




The aims of this project were to investigate the relationship between the 
concentrations of serum lipoproteins and the excretion of the sex hormones in 
normal men in order to answer the following questions: (1) Do endogenous sex 
hormones contribute to the variation in serum lipoprotein-lipids? (2) To what 
extent do sex hormones affect the plasma lipoprotein-lipids? (3) I f the excretion 
of urinary sex hormone reflects the secretion rate and the production rate of the 
endogenous sex hormones, do urinary sex hormone excretions account better for 
variation in plasma lipoprotein-lipids than serum sex hormone concentrations? 
(4) Wi l l the urinary free Cortisol which reflects its production rate explain more 
clearly in its association with serum lipoproteins? 
10 
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Chapter II. Literature Review 
II.l. Lipoprotein-Lipids 
11.1.1. General Concept and Metabolism of Lipoprotein-lipids 
Al l lipids from dietary sources or body synthesis, except non-esterified 
fatty acid (NEFA) which is bound by albumin, are transported in plasma in the 
form of lipoproteins. The spherical particles of lipoproteins of varying sizes 
have unique flotation rates (sf), hydrated densities (d), and electrophoretic 
mobilities. Based on the physical properties of plasma lipoproteins, six distinct 
classes of lipoproteins can be isolated from postprandial plasma, namely 
chylomicrons (d <0.95 g/ml), VLDL (very-low-density lipoproteins, d <1.006 
g/ml), IDL (intermediate-density lipoproteins, d =1.006-1.019 g/ml), LDL (low-
density lipoproteins, d =1.019-1.063 g/ml), HDL (high-density lipoproteins, d 
= 1.063-1.21g/ml) and Lp(a) [lipoprotein(a),d=1.051-1.082g/ml]. 
Apolipoproteins are the protein fractions of the lipoprotein particles that react 
with a series of enzymes and/or tissue receptors, and are responsible for further 
metabolism of the particles. A lipoprotein molecule consists of an outer 
monolayer of apolipoprotein and polar lipids (phospholipid and free cholesterol) 
and an inner core of neutral lipids (triglyceride and esterified cholesterol) which 
is non-polar (Tietz^, 1986). Lipoproteins also differ importantly in terms of their 
content of apolipoproteins. For example, apoA is mainly associated with HDL, 
apoB with LDL, apoE with VLDL and VLDL- and chyromicron remnants, apoC 
with chylomicrons and VLDL, and apo(a) with Lp(a). There are heterogeneities 
of apolipoproteins which may have structural, metabolic and/or genetic 
significance of the lipoproteins, such as apoA-I and apoA-II for apoA; ApoB48 
and apoBlOO for apoB; the subunits of apo(a) for Lp(a). ApoA-I plays a central 
role in determination of the structure and plasma concentration of HDL, and 




1992; Cheung et al” 1993). ApoBlOO is the ligand for the L D L receptor, but 
apoB48 which is associated with chylomicron does not bind with it (Thompson, 
1990). The apo(a) isoforms, associated with high Lp(a) plasma concentrations, 
may represent a stable genetic trait in subjects with CHD in different populations 
(Sandholzer^ et. al” 1992). In the apoE4 phenotype subjects tend to have higher 
level of total cholesterol in the body whereas in apoE2 homozygous phenotypes 
higher level of VLDL cholesterol (Mahley and Innerarity, 1983; Kes^ iemi et 
al” 1987; Mahley, 1988). It is known that subjects with apoE2 homozygous 
phenotypes, in combination with a second independent metabolic disorder, 
develop Type I I I hyperlipoproteinemia (Feussner et al” 1990). (For review, see 
Bhatnagar and Dumngton, 1991). 
Most of the cholesterol in the plasma of fasting normal subjects is carried 
by LDL-C, the rest being found in VLDL-C, and HDL-C. Most of the 
endogenous triglyceride is carried by VLDL. Thus, measurement of the total 
cholesterol and triglyceride in the fasting state plasma (usually after a 12-hour 
fast) gives the sum of the contributions from each lipoprotein class. Under 
normal circumstances there are virtually no IDL-C or chylomicrons found in 
fasting plasma. However, raised IDL-C or chylomicrons remnants, as in type I I I 
hyperlipoproteinemia, are thought to increase the risk of atheromatous disease 
because the macrophages and other cells of the reticuloendothelial system take up 
these remnants to form foam cells in the arterial wall. Similar mechanisms also 
take place for L D L particles modified by acetylation or peroxidation in vivo. 
Thus high plasma levels of LDL-C show a marked direct association with 
atheroma formation (Fuster et al” 1992). An alternative means of quantitating 
LDL-C is to measure apoB in LDL-C. Because there is one apoB molecule to 
each L D L particle, apoB provides a better index of the number of L D L particles 
present in plasma (Levinson and Wagner, 1992). 
10 
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LDL is the major extracellular cholesterol source for cells. A l l human 
cells obtain and degrade LDL through the LDL-receptor pathway. The LDL 
receptor is a transmembrane glycoprotein on the surface of most cells in the 
body. It has high binding affinity for the apoB molecule in an LDL particle. 
Once LDL is internalized, it is transferred into lysosomes and digested by 
lysosomal enzymes. The cholesteryl ester in the central core of the LDL particle 
is hydrolyzed and free cholesterol is released and becomes available for 
steroidogenesis (in liver, gonads, adrenal cortex and placenta), for formation of 
lipoproteins, and for conversion into bile acid for excretion by the liver (Brown 
and Goldstein, 1986). ApoE also can be recognized by LDL (B, E) receptors on 
liver cells and is responsible for the removal of the remnants produced by the 
action of lipoprotein lipase on VLDL. Therefore, decreased activity of hepatic 
LDL receptors wi l l result in a fall in the rate of VLDL remnant removal from the 
circulation. Other receptors are also present in human cells, such as the apoE 
receptor, which only recognizes lipoproteins containing apoE, but does not 
recognize LDL. Receptors recognizing apoE on chylomicron remnants mediate 
their rapid removal from the circulation after a fatty meal (Mahley and Innerarity, 
1983; Mahley, 1988). 
Fatty acids are stored in adipose tissue as triglyceride. The mobilization 
of triglyceride is controlled by a hormone-sensitive lipase, the activity of which is 
enhanced by hormones such as noradrenaline and the glucocorticords and 
inhibited by insulin. Lipolysis results in the release of non-esterified fatty acid 
(NEFA) and glycerol into plasma. NEFAs are carried by albumin to the liver, 
heart and skeletal muscle where oxidation of fatty acid is carried out. NEFAs 
are also taken up by the liver and are re-esterified to triglycerides and 
phospholipids. Phospholipids are the important components of all cell membranes 
due to their amphipathic nature, by which the membrane is able to interact with 
10 
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non-polar (lipoid) and polar (aqueous) environments. Changes of phospholipid 
composition in the cell membrane may cause membrane damage (Borkman et al” 
1993). For instance, the immune-induced hydrolysis of (glomerular epithelial 
cell) membrane phospholipid might account for the development of glomerular 
membranous nephritis as in the case of passive Heymann nephritis (Weise et al” 
1993). 
Besides being an essential component of the membranes of all human 
cells, the myelin sheaths of nerves, and the outer shell of plasma lipoprotein 
particles, cholesterol also acts as the precursor of bile acids and steroid hormones 
which are the major routes of elimination of the synthesized and dietary 
cholesterol from the body. Bile acids are the major metabolites of cholesterol in 
the liver, with the rate-limiting enzyme being cholesterol 7-a-hydroxylase which 
is negatively fed back by bile acids, the end product. The biosynthesis of 
cholesterol takes place in all human cells. It begins with transformation of acetic 
acid to acetyl CoA, and then to the 6-carbon compound, mevalonic acid. Six 
mevalonic acid molecules condense to form squalene, which is then hydroxylated 
and converted to a 27-carbon skeleton of cholesterol. The rate-limiting enzyme is 
P-hydroxy-P-methylglutaryl-CoA (HMGCoA) reductase which is important in the 
formation of mevalonic acid from the reduction of HMG-CoA. HMGCoA 
reductase is subject to negative feed-back by its end product, cholesterol. 
During metabolism of living cells, the esterification of free cholesterol is 
enhanced by an enzyme ACAT (acyl-CoA-cholesterol acyltransferase) which 
transfers the fatty acid residue of acyl-CoA to cholesterol. In plasma, lipolysis of 
chylomicrons and V L D L by lipoprotein lipase (LPL) results in the release of 
triglycerides, free cholesterol, phospholipids, and apolipoproteins, leaving the 
hydrolyzed particles (remnants). The remnants acquire apoE from other 
lipoproteins, which serves as the ligand for LDL receptor present in the liver for 
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clearance and catabolism of remnants. The released particles are then transferred 
to the small, dense HDL3 particle where similar esterification of free cholesterol 
is also enhanced by an enzyme LCAT (lecithin-cholesterol acyltransferase) to 
form HDL2 by transferring fatty acid residues from phospholipids (lecithins) to 
free cholesterol. This process is associated with reverse cholesterol transport 
through HDL (Witztum and Schonfeld, 1979; Myant, 1991). The cholesteryl 
ester of the derived HDL particles that acquire apoE (HDL2), on the other hand, 
can also be exchanged from HDL2-C into VLDL or L D L by cholesteryl ester 
transfer protein (CETP). CETP is a hydrophobic glycoprotein which binds to 
triglyceride-rich particles and circulates in a complex with LCAT. This CETP-
mediated cholesterol exchange into the apoB-containing lipoprotein (LDL or 
VLDL) wi l l facilitate the removal of cholesterol when V L D L and L D L particles 
are taken up by L D L receptors. CETP is associated with the regulation of HDL 
cholesterol, since by transferring the cholesteryl esters from HDL2-C via CETP, 
HDL2 particles are redigested by hepatic lipase to generate HDL3. The complex 
interactions of lipoprotein lipase activity, hepatic lipase activity and fasting HDL2 
levels determine the postprandial triglyceride levels (Silverman et al” 1993). The 
reverse transport of cholesterol by HDL plays a key role for cholesterol removal 
from the body, and thus in the function of regression of atherosclerosis (Badimon 
etal” 1992). 
The studies on the role of plasma triglyceride levels as a risk factor for 
coronary heart disease have been controversial (Barbir et oL, 1988; Austin, 1989, 
Criqui et aL, 1993). However, the four well-known American studies 
[Framingham Heart Study (FHS), Lipid Research Clinics Prevalence Mortality 
Follow-up Study (LRCF), Coronary Primary Prevention Trial (CPPT), and 
Multiple Risk Factor Intervention Trial (MRFIT)] and the British Regional Heart 
Study (BRHS) have shown a consistent inverse correlation of HDL-C levels and 
10 
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coronary heart disease mortality rate when differences in analytic methodology 
were eliminated (Gordon et al, 1989). The predictic value of HDL-C for the 
overall mortality rates of CVD and/or CAD has been proved better than that of 
the sole measurement of total cholesterol and/or LDL cholesterol (Kannel and 
Wilson, 1992). In addition to HDL-C, other work has shown that levels of 
HDL2-C, a subfraction of HDL-C, are closely inversely related to cardiac 
vascular disease as in angiographic studies (Miller, et al” 1981; Johansson et al” 
1991; Drexd et al.，1992). 
Any defects or changes in the rate-limiting enzymes (HMGCoA reductase, 
cholesterol 7-a hydroxylase, LCAT, ACAT, LPL), and/or in receptors (e.g. 
apoB or apoE receptors) and CETP by intrinsic or extrinsic factors may result in 
abnormalities and/or changes of lipoprotein-lipid levels in plasma. Treatment of 
hyperlipidaemias with drugs is based on the principles of increasing the clearance 
of apoB-containing lipoproteins by increasing LDL-receptor activity, on 
lowering hepatic cholesterol synthesis or draining cholesterol with bile acids by 
sequestration in the distal small gut with resins. Other drugs may work by 
reducing VLDL production, such as nicotinic acid. (Kannel and Wilson, 1992; 
Scott, 1993). 
Lp(a) is a unique lipoprotein with a density between those of LDL-C and 
HDL-C. There are resemblances of structural and biochemical properties of Lp(a) 
and LDL-C. Lp(a) is not a metabolic product of VLDL-C, LDL-C, or 
chylomicrons, and Lp(a) is not converted to other lipoproteins. It has an 
independent synthetic pathway (Krempler et al, 1980; Houlston and Friedl, 
1988). Apo(a) which is the protein moiety of Lp(a), links to apoB-100 by a 
disulfide bridge and serves as distinctive marker for Lp(a) levels in plasma. The 
size of apo(a) isoforms reflected in Lp(a) concentrations, is an independent risk 
factor for predicting the development of coronary heart disease, and is controlled 
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by the apo(a) gene. There is an inverse relationship between apo(a) size and 
plasma Lp(a) level (Sandholzer^ et al” 1992). A person's Lp(a) is genetically 
controlled, independent of age and sex and the plasma concentration of Lp(a) is 
uniquely stable throughout the whole life span (Lawn, 1992). However, the 
apo(a) gene only accounts for 40% of the variation in Lp(a) levels, and other 
factors must contribute (Utermaim et al, 1989; Scanu and Fless, 1990). Among 
these, cyclosporin (Webb et aL, 1993), nicotinic acid (Gurakar et al, 1985; 
Carlson et al” 1989; Schmidt et aL, 1993)，fish oil (Scanu and Fless, 1990; Fu et 
al” 1991), and androgens, estrogens, and growth hormone (Parish et al” 1991; 
Henriksson et al” 1992; Eden et al, 1993), as well as pregnancy (Panteghini and 
Pagani, 1991) are good examples. Nevertheless, a more recent paper has 
suggested that the apo(a) gene is responsible for 91% of the variance of plasma 
^ Lp(a) concentration (Boerwinkle et al” 1992). 
IL1.2. Factors affecting plasma lipoprotein-lipids 
Intrinsic (genetic) and extrinsic (environmental) factors both affect the 
plasma levels of lipoprotein-lipids. Sometimes it is difficult to differentiate these 
two factors, because they interact and the combined effects may be difficult to 
predict. 
11.1,2.1. Ageing 
It has been well documented that age is an important source of variation 
of plasma lipoprotein-lipid concentrations in both men and women. There is an 
age-related increase of total cholesterol and LDL-C values in men, and in women 
not taking sex hormones, between the ages 20-50 years, while the change of 
HDL-C with age is less prominent and the level remains rather stable at this age 
range in both sexes. In males, triglyceride and VLDL-C increase with age with a 
parabolic relationship (an acme is reached between the ages 40-44), while in 
females a curvilinear increase with age is observed. (Heiss et al” 1980). Ageing 
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is also frequently accompanied by an increase in body weight, a decrease in 
physical activity and changes in hormonal levels, as in the case of 
postmenopausal women (Thompson, 1990; Stevenson et al” 1993). In men, there 
is an age-related decline of serum total and bioavailable testosterone (Dai et al” 
1981; Nahoul and Roger, 1990). 
ILl.2.2. Obesity 
Adiposity is an important source of variation in plasma lipoprotein-lipids 
levels. An increase in the levels of triglyceride and VLDL-C is found in many 
obese individuals, although there is little relationship between total cholesterol 
and obesity (Bray, 1989). However, it is well known that there is an inverse 
relationship between HDL-C and obesity (Stunkard et al., 1981; Stubbe et al” 
1983; Bray, 1989). Furthermore, adiposity has effects on sex-hormone levels and 
SHBG concentrations. In terms of body mass index (BMI) (expressed by the 
ratio of body weight in kilograms and the square of height in meters) (kg/m^) 
adiposity affects the physiological hormonal levels in body. In men, androgens 
decrease (Zumoff et al, 1990) and estrogens increase with obesity (Segal et al” 
1987). The reduction in total testosterone is usually accompanied by a reduction 
in the level of SHBG and the fall in SHBG is associated with a rise in the 
concentration of estradiol and estrogen in the plasma in moderately obese men 
(Bray, 1989). In morbidly obese men, higher estrogen and lower androgen and 
sex hormone binding globulin concentrations than those in normal-weight 
subjects are observed (Segal et al” 1987; Pasquali et al” 1988). In women, the 
secretion of estrogen decreases on reaching the menopause, with increased 
adiposity (Kuller et al” 1990; Stevenson et a l ” 1993). The body composition-
related sex steroid alterations may affect the lipoprotein-lipids profile (Segal et 
al., 1987). The body fat distribution in terms of waist and hip ratio (WHR) 
(Terry et aL，1989), abdomen-hip ratio (AHR) and triceps skinfold (Houmard et 
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al” 1991), is also important although the associations with serum lipoprotein-
lipids level and hormones are less clear. It is postulated that thigh fat may 
contribute to lipoprotein profiles that predict lower risk of cardiovascular disease 
(Seidell et al” 1989; Terry et al., 1991). 
IU.2.3. Diet 
Both total fat and fatty acid composition are important determinants of 
plasma cholesterol levels. Saturated fats raise the serum cholesterol and 
triglyceride levels whereas polyunsaturated fats cause them to decrease. In a 
small number of male subjects, changing the diet from high to low fat content for 
a short period of time (2 weeks), reduced the cholesterol level significantly (Reed 
et al, 1987). However, recently it was found that stearic acid (C18, saturated 
fatty acid) is unique and has an independent effect of lowering plasma cholesterol 
level {Derr et al, 1993). Genetic traits and the body's self-regulating metabolic 
mechanisms (e.g. rate-limiting enzymes in cholesterol synthesis and excretion) 
cause a marked variability of response between individuals (Quivers et al” 1992). 
Vegetarians have lower cholesterol and non-HDL cholesterol than non-
vegetarians (Sacks et al” 1975; Masarei et al” 1984)，perhaps because the sterols 
of plant origin are not only very poorly absorbed but also inhibit the absorption 
of cholesterol, probably by competing with cholesterol for esterification with 
fatty acid, but possibly also due to the effects of different lengths and saturation 
of plant fatty acids and their effects on lipid metabolism. 
ILl.2.4. Alcohol 
A regular, moderate intake of alcohol wil l increase the level of HDL-C in 
plasma (Castelli et al.，1977; Masarei et al” 1986; Puddey et al” 1986; 
Marinetti, 1990; Valimaki et al.，1991). This effect is independent of all other 
variables. However, after acute ethanol administration, there is an increase in 
triglycerides without change in HDL-C (Mishra et al” 1991). 
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ILl.2.5. Cigarette smoking 
Cigarette smoking has a negative correlation with HDL-C, while a study 
on cigarette smoking cessation has shown an increase in plasma concentration of 
apolipoprotein A- I I (Masarei et al” 1991). 
ILl.2.6. Exercise 
Lipoprotein metabolism, especially the lipolytic rate of triglyceride-rich 
lipoproteins, is influenced by physical training, increasing with increasing 
activity. Vigorous activity in men wi l l increase plasma HDL-C level as the result 
of an increase in the HDL2 subfraction and apolipoprotein A-I. (Wood and 
Haskell, 1979; Kiens, 1992). 
IL1.2.7. Gender differences 
In Caucasians, females have higher total-HDL-C and HDL2-C levels in 
plasma than males (Anderson et al” 1978; Martini et al” 1984; James et al” 
1989; James and Pometta, 1990; Atger et al, 1990). Females tend to have 
lower triglyceride, LDL-C, VLDL-C and higher HDL-C levels than men from 
puberty onwards until menopause but thereafter those in females become higher 
than in men of similar age, except those who take hormone replacement therapy 
(HRT) (Heiss et al” 1980). This sex-differential variation in HDL2-C may be 
due to lower levels of hepatic lipase (HL), resulting in a lower rate of removal of 
HDL-C, and faster triglyceride clearance due to higher lipoprotein lipase (LPL) 
in females. (Godsland et al, 1987; Seed, 1991 for review). The sex-difference in 
HDL2-C levels can be compensated for in part by exercise in men (Wood and 
Huskell, 1979). An inverse relationship between HDL2-C and postprandial 
catabolism of triglyceride (Patsch et al” 1983), a direct relationship between 
HDL2-C and lipoprotein lipase (Taskinen and Nikkila, 1981, Patsch et al” 
1987)，and an inverse correlation between HDL2-C and hepatic lipase activity 
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(Patsch et al” 1987) have been documented. 
11.2. Sex Hormones 
IL2.1. General concepts of sex hormone-production and the 
metabolism of sex hormones 
Hormone concentrations in blood are kept relatively constant because the 
ratio between their secretion and disposal rates is rather constant. The secretion 
rate for a hormone is defined as the rate at which the hormone is secreted from 
the sum of the endocrine glands, which is expressed as the amount of hormone 
secreted per unit of time (e.g. jig/day). I f the hormone is secreted by one gland, 
then the secretion rate is equal to production rate as is the case with Cortisol and 
aldosterone. However, sex steroids such as estradiol and testosterone are 
secreted by the gonads and are also produced in peripheral tissues by the 
transformation of hormonally inactive steroid precursors through metabolic 
processes (extraglandular transformation). Therefore the production rate of a 
steroid hormone is equal to the sum of its secretion rate and transformation rate. 
On the other hand the metabolic clearance rate (MCR) is defined as the apparent 
volume of whole blood or plasma from which a substance is completely and 
irrevocably removed per unit of time. There is a close relationship between 
hormone binding in plasma, the hepatic extraction and MCR. I f the MCR 
remains constant, a decrease in plasma concentration reflects accurately the 
decrease in production rate. However, i f the binding capacity of serum is 
increased, then the MCR wil l be decreased, since tissue extraction and 
metabolism are reduced. The MCR of sex steroids is inversely related to the 
relative binding affinity to SHBG. (Lipsett, 1986). 
SHBG, also known as TeBG (testosterone-estradiol binding globulin) and 
SBP (Sex steroid binding protein), is a circulating glycoprotein with molecular 
weight about 80,000 to 90,000. It is synthesized in the liver, and its biological 
function in the circulation is the transport of sex steroid hormones. It has high 
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affinity binding (10^ L/mol) (Anderson, 1974), therefore, SHBG-bound steroids 
are not readily available for target tissue binding and action. However, it has a 
low capacity for sex-hormone binding，one binding site per mole (Yen, 1986). 
Although the serum unbound or "free" fraction of sex steroids is readily 
available for biological action at the target cells, loosely albumin-bound fractions 
and the fraction represented by salivary sex steroids are also considered to be 
biologically active (Wong et al” 1990; Pardridge, 1991; Swinkels et oL, 1991). 
The binding affinity of SHBG for testosterone at 37°C is much greater than that 
of serum albumin. In comparison to the binding affinity for testosterone, the 
affinity of SHBG is about three times as great for DHT, and for estradiol only 
about one third. Androstenediol binds less strongly than does testosterone 
(Anderson, 1974). There is virtually no SHBG binding of androstenedione and 
DHEA (Yen, 1986). 
11.2.1.1. Biosynthesis of testosterone 
In men, the synthesis of testosterone is almost exclusively controlled by 
the hypothalamic-pituitary-testicular axis. The hypothalamus secretes 
gonadotropin-releasing hormone (GnRH) which stimulates the anterior segment 
of the pituitary gland, located at the base of the brain, to release luteinizing 
hormone (LH) into the blood stream. The L H then stimulates the Leydig cells of 
the testis to synthesize and secrete testosterone into the circulatory system. 
Cholesterol is the precursor of steroid hormones, and may be obtained from 
LDL-cholesterol in the blood or from de novo synthesis from acetate. In the 
human, the major biosynthetic pathway is via the A^-pathway including 
pregnenolone, 17-hydroxypregnenolone, and androstenediol. Testosterone and 
androstenedione are the end-products which are secreted into the blood and are 
converted to estradiol and estrone respectively, at extraglandular sites in 
peripheral tissues. Moreover, androstenedione can be converted to testosterone 
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(Lipsett, 1986). Thus the production rate of serum testosterone is the sum of 
secretion rate of testosterone and the production rate of testosterone from 
androstenedione. 
11.2,1.2, Metabolism of testosterone 
When testosterone enters a cell, it may be metabolized by two pathways. 
One is from testosterone -> DHT 5-a-androstenediol, of which the end-
metabolites DHT and 5-a-androstenediol are more potent than testosterone at the 
tissue level. Another is from testosterone androsterone -> etiocholanolone, of 
which the end-metabolites are less potent and are conjugated in the liver and 
excreted in the bile or the urine. It is believed that both types of metabolism 
could occur in a sequential manner in the same cell. In either pathway, the 
metabolism of testosterone is accomplished by a change in steroid structure 
(Bardin, 1986). Non-conjugated, biologically active testosterone in circulation 
may also be filtered at the glomerulus and excreted in the urine (Lipsett, 1986). 
In total, the outcomes of the metabolism of testosterone can be classified 
into three aspects (Bardin, 1986) as follows: 
(1) The biopotency of testosterone is modified by aromatization to a potent 
estrogen, 17P-estradiol. This provides significant local concentrations of 
estrogens in individual tissues and contributes significantly to the blood estrogen 
level. 
(2) The biological activity of testosterone is amplified by 5a-reductase which 
reduces the major blood androgen (testosterone) to the more potent DHT and 5a-
androstenediol at the tissue level, especially in tissue of the male reproductive 
tract and skin. 
(3) The biological activity of testosterone is modified by the action of 5P-
reductase. The consequence of this reaction is to produce 5P-DHT and 5p-
reduced steroid (etiocholanolone) which are then further metabolized to sulphate-
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or glucuronide- conjugated 17-ketosteroids in the liver and excreted in the 
urine. Only about 1% of secreted testosterone is excreted in the urine as the 
testosterone-17p glucuronide (Horton, 1989). 
Since substantial amounts of androstenedione and other adrenal androgens 
(such as DHEA and DHEA-sulfate) are also metabolized to 17-ketosteroids, it is 
now clear that the determination of total urinary ketosteroids is a poor reflection 
of testosterone secretion and androgenicity. However, the measurement of 
urinary total testosterone (the sum of unconjugated testosterone and testosterone-
17(3 glucuronide and /or sulfate in urine) is an index of testosterone production in 
blood and in tissue (Camacho and Migeon, 1964; Korenman and Lipsett, 1964). 
11.2.1.3. Dihydrotestosterone (DHT) 
Although it is the most potent form of testosterone at the tissue level, it is 
only secreted in small amounts by the testis, and contributes very little to the 
overall androgen content of the blood in men. There is little free DHT in the 
circulation because it has stronger binding affinity to SHBG than does 
testosterone. Testosterone and androstenedione are precursors of plasma DHT. 
Testosterone accounts for at least 70% of plasma DHT in men. (Horton, 1989). 
11.2.1.4. Androstenedione 
Leydig cells secrete small amounts of androstenedione, and the remainder 
is secreted by the adrenal cortex or derived from dehydroepiandrosterone 
(DHEA) by peripheral tranformation (Bardin, 1986). The adrenal output of 
androstenedione is responsive to adrenocorticotropic hormone (ACTH) 
stimulation and exhibits a diurnal rhythm coincident with that of Cortisol (Yen, 
1986). 
IL2.1.5, Biosynthesis of estrogen in men 
Testes secrete estrogenic hormones, but under normal conditions 
account for only a negligible amount of that present in blood (Bardin, 1986). 
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The major portions of blood estradiol and estrone in normal men are derived 
from blood testosterone and androstenedione, respectively. This conversion of 
androgens to estrogens requires cytochrome p-450-dependent aromatase which is 
present in many non-endocrine tissues. (Bardin, 1986). 
IL2.1.6, Metabolism of estrogen 
The estrogens are preferentially conjugated with glucuronic acid, sulfates, 
and /or mixed conjugates, as well as other polar conjugates in the liver and 
excreted in the urine. (Lipsett, 1986 ). 
77.2.2. Factors affecting sex hormone levels in plasma 
Several variables should be borne in mind when one considers the levels 
of sex hormones in a subject. 
11.2.2.1, Sex hormone binding globulin (SHBG) 
Variation in sex hormone levels in adults may be due to in part the 
differences in SHBG levels. Adult women have twice the plasma concentration of 
SHBG of adult men. This sex difference is due to the fact that SHBG production 
is promoted by estrogen and inhibited by androgen. The level of circulating 
SHBG is considered a major controlling factor in the balance between 
biologically active androgens and estrogens (Anderson, 1974; Yen, 1986). SHBG 
levels in turn are affected by obesity, a variable which also shows strong 
associations with lipid levels, so obesity needs to be taken into account when 
evaluating associations between sex hormone levels and lipids. 
This relationship of sex hormones and binding proteins is an important 
factor in the interpretation of circulating hormone levels and biologic action at 
target tissues. 
77.2.2.2. Sampling time 
The secretion of testosterone is episodic or pulsatile. (Yen, 1986; Smith 
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and Rodriguez-Rigau, 1989), and the same is true of estradiol, as most of the 
estradiol in men is derived from the aromatization of testosterone and 
androstenedione (Bardin, 1986). Single values of sex steroid concentrations 
should be interpreted with caution. Estimates may be improved by utilization of 
multiple or integrated blood-sampling techniques (Smith and Rodriguez-Rigau, 
1989). 
IL2.2.3. Stress and acute or chronic non-endocrine illnesses 
In hemodialysed patients (Bogicevic and Stefanovic, 1988) and male 
patients with respiratory failure (Kouchiyama et aL, 1989), the serum level of 
testosterone is decreased. In kidney stone patients (Van Aswegan et al” 1989), 
the urinary level of testosterone was lowered. The plasma DHEA-S and DHT 
concentration in young men is decreased after a myocardial infarction 
(Slowinska-Srzednicka et al” 1989). In patients with septic shock, there is a 
dramatic increase in estrone and estradiol, associated with a decrease in 
testosterone in plasma (Christeff et al” 1988). Persons with ischemic heart 
disease have significantly lower testosterone levels than persons without ischemic 
heart disease (Lichtenstein et al” 1987). Patients with positive coronarographic 
findings have low levels of testosterone (Hromadova et al” 1985). Serum total-
and free- testosterone were 30% lower in hypertensive than in normotensive men 
(Hughes et al” 1990). In patients with premature coronary vascular disease, 
testosterone concentration was significantly lower than that in normal healthy 
Indian men (Sewdarsen et al” 1990). Overproduction of corticosteroids has been 
reported to suppress testosterone levels in normal adult males. The increased 
Cortisol level due to surgical stress may contribute to the suppressed level of 
testosterone (Doerr and Pirke, 1976). 





It has been found that 24-hour mean integrated plasma testosterone levels 
are decreased in healthy older men (Zumoff et al” 1982). Also in adult men the 
bioavailable testosterone levels decline significantly with age while those of total 
testosterone decrease less significantly (Dai, et al” 1981; Nahoul and Roger, 
1990). Some investigators have reported that the age-related reduction in free 
testosterone is due to the age-related increase in sex hormone-binding globulin 
capacity rather than a reduction of total serum testosterone. The consequent 
reductions in free testosterone are dispropotionate to those of total testosterone 
(Blackmail, 1989). It is said that the urinary total testosterone is age dependent, 
as a distinct decrease in total urinary testosterone is observed in elderly persons 
(Van Aswegan et al” 1989). The plasma level of DHEA-sulfate decreases with 
aging (Orentreich et aL, 1984). 
11.2.2,5. Diet and nutrition 
A western diet increases and a vegetarian diet decreases the urinary 
testosterone excretion in men and this is accompanied by changing serum 
lipoprotein profiles (Hil l et al” 1980). 
It appears that energy surfeit has an effect on blood hormone 
concentrations as overfeeding female subjects results in weight gain with 
increased plasma somatomedin-C/insulin-like growth factor, testosterone and 
insulin (Forbes et al” 1989). It has been demonstrated also that dietary lipid 
intake is an additional factor involved in the regulation of plasma levels of SHBG 
in normal men. After consuming a diet with a high fat content ( > lOOg fat/day) 
for two weeks, the mean SHBG level decreases (mean total cholesterol level 
increases). Changing the diet from one with a high fat to low fat content 




mean plasma cholesterol level, while the mean SHBG level increases. The 
increase in plasma SHBG is associated with a significant decrease in the free 
testosterone fraction and free testosterone concentration (Reed et al” 1987). 
II. 2.2.6. Medication, drugs and alcohol 
Antifungal drugs such as Ketoconazole and Fluconazole when taken orally 
wi l l block adrenal steroidogenesis by inhibition of cytochrome p450-dependent 
enzyme (aromatase) (Contreras et al” 1985; Devenport et al” 1989). 
Feminization due to generalized increase of aromatase in peripheral tissues can 
be treated with an aromatase inhibitor (Bardin, 1986). Antiandrogens such as 
progesterone, cyproterone acetate, flutamide, or spironolactone generally 
demonstrate high receptor affinity but do not activate or lead to translocation of 
the antiandrogens-receptor complex. Most of these substances also suppress L H 
and thus reduce testosterone secretion (Horton, 1989). 
It has been shown that athletes who take 110-116 grams of ethanol [about 
2g/kg body weight] in six hours wi l l increase the ratio between testosterone and 
epitestosterone in urine, most likely due to the increase of testosterone (Falk et 
al” 1988). 
IL2.2,7. Body composition and obesity 
It was reported that morbidly obese men have higher estrogen and lower 
dehydroepiandrosterone sulphate (DHEAS), testosterone (total and free) and 
SHBG concentrations than control normal-weight subjects (Pasquali et al” 1988). 
Zumoff et al. (1990) found that plasma calculated 'free' testosterone and non-
SHBG-bound testosterone (both are biologically active) are decreased in obese 
men in proportion to their degree of obesity. However, early reports suggested 
that the reduction in total testosterone in moderately obese men is accompanied 
by a reduction in the level of SHBG, resulting in a normal level of free 
testosterone (Amatruda et al” 1978). In non-obese females, increased androgenic 
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activity (ratio of free testosterone to total testosterone) and degree of obesity 
(BMI) are independently related to increased waist-hip ratio (Seidell et al” 1989). 
It was also reported that plasma sex-hormone binding globulin and percent free 
testosterone are associated with regional adiposity in sedentary middle-aged men, 
but do not account for the correlations between WHR and lipoproteins (Terry et 
al” 1989). Nevertheless, it has been concluded that body composition as 
reflected by body mass index rather than body weight is associated with sex 
steroid alterations, with consequent changes in plasma lipoprotein profiles 
(Segal et al, 1987). 
11.2.2.8. Variations in states of sleep-wake cycle 
There is evidence for a circadian rhythm of testosterone secretion in 
young men. The acrophase of the rhythm is about the time of awakening, and 
the nadir is in the evening; the amplitude is small (10 to 25 per cent). There is a 
sleep-related rise of L H and testosterone level during puberty in boys. The 
circadian rhythm of testosterone in young adults may be a result of a persistent 
sleep-related rise in this steroid. It may ultimately disappear with advancing age 
(Bardin, 1986). 
11.2,2.9. Levels of physical and sympathetic nervous system activity 
Earlier studies showed that the urinary free and total testosterone levels in 
sportswomen were markedly higher in comparison with those of the inactive 
females. Recently several studies have indicated that exercise induces an acute 
elevation in the circulating testosterone levels, while exercise on a regular basis 
has been demonstrated to affect the resting levels of testosterone. Both the 
acute and long term testosterone responses to exercise are determined by the 
mode, intensity and duration of the exercise (Deschenes et al, 1991; Galbo, 
1991). It has been reported that endurance trained male athletes demonstrate a 




to endurance training, weight-training has been demonstrated to increase resting 
levels of testosterone. It was found that significant correlations exist between 
increases in strength and elevations in the free to bound testosterone ratio 
(Deschenes, et al., 1991 for review). 
However, even a modest, achievable exercise program for men with 
premature myocardial infarction can also be beneficial by ameliorating their 
hyperestrogenemia and reducing atherogenic factors (Mendoza et al” 1991). 
Subjects with Type A behavior pattern exhibit a chronic excess discharge 
and circulation of catecholamines from nerve endings and hormones from the 
pituitary, adrenal and pancreatic glands. The overstimulating of the sympathetic 
nervous system leads to increased intravascular deposition of the clotting 
elements of the blood and an excess of the insulin in their blood indicating 
abnormal disposition of fat and sugar metabolism in the body (Friedman & 
Rosenman, 1975). Although elevated day time urinary excretion of 
testosterone glucuronide in men with the type A behavior pattern was found 
(Zumoff et al” 1984)，it was reported that type A and type B behavior patterns 
are not correlated with testosterone concentration in serum (Dai et al” 1981). 
Interestingly, factors affecting both sex hormone levels and lipoprotein-
lipids are similar and may imply a relationship between sex hormones and 
lipoprotein-lipids. 
11.3. The relationship between sex hormones and 
lipoproteins 
11.3.1. Gender difference in sex hormones, menopause and 
lipoprotein-lipids 
The association between hyperlipidaemia and atherogenesis is well 
established biochemically both from human and animal studies. Much 
epidemiologic data indicates that the concentrations of plasma lipoprotein-lipids 
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may be better predictors of risk for atherosclerosis than are the levels of total 
plasma lipids alone (Miller, et al” 1981, 1987; Johansson et al” 1991; Drexel et 
aL, 1992, Levinson and Wagner, 1992). Levels of HDL-C among white 
Americans are similar in boys and girls before puberty. As boys mature sexually, 
their levels of HDL-C，especially the HDL2 fraction, fall below those of girls and 
remain so throughout the whole of adult life. In contrast, there is no such drastic 
change in girls, their levels of HDL2 remaining high until the menopause. After 
the menopause, the levels of HDL-C and HDL2-C fall, and the levels of total 
cholesterol, total triglyceride, and LDL-C increase except in those who take 
hormone replacement therapy (HRT) (Heiss et al, 1980). This unique lipoprotein 
profile in menopause/postmenopausal women is demonstrated by epidemiologic 
studies (Kuller et al, 1990; Jensen et al, 1990; Stevenson et al” 1993) and is 
believed to be mediated by estradiol. Concomitantly, the incidence of CAD in 
males is higher than in pre-menopausal females, and the incidence of CAD in 
postmenopausal women is higher than that of premenopausal. Raised serum LDL-
C levels are also noted in surgical menopause (bilateral oophorectomy) (Parish et 
al” 1990). It is reported that postmenopausal women who are on HRT have less 
risk of mortality due to CHD (Knopp, 1988; Barrett-Connor and Bush, 1991). 
The protective effect of estrogen may be mediated through increased HDL-C levels 
(Bush et al” 1987; Mattews et al” 1989)，although other beneficial effects on 
arterial wall by preventing development of aortic and coronary atheroma are also 
proposed (Adams et al” 1990). 
IL3.2. Interventional study，exogenous sex hormone and 
lipoprotein-lipids in men 
In an interventional study in a small number of normal men, the 
suppression of plasma testosterone by a long-acting gonadotropin releasing 
hormone analog (LHRHA) leads to an increase in serum total cholesterol, HDL-C, 
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and apolipoprotein A l and B (Goldberg et aL, 1985). Unlike the effect of 
androgenic steroids as used by healthy young athletes, which results in a fall of 
serum HDL-C, intramuscular administration of exogenous, aromatizable 
testosterone (testosterone enanthate) does not induce androgen-induced hepatic 
triglyceride lipase activity nor decrease the HDL-C level (Friedl et al” 1990). 
However, in a study of a group of young sterile testosterone-deficient men, 
treatment with exogenous methyl testosterone orally restored the level of 
testosterone, and improved the initial dyslipidaemia due to testosterone deficiency. 
The lipid profiles were normalized with the restored testosterone level with 
decreasing triglyceride, LDL-C, apoB and increasing HDL (Hromadova et al” 
1991). 
11.3.3. The relationships of endogenous sex hormones and 
lipoprotein-lipids 
Masarei et al (1980) documented that endogenous plasma estradiol has a 
weak positive correlation with HDL-C, while plasma SHBG is strongly positively 
correlated with HDL-C in both post- and pre-menopausal women. The subsequent 
studies performed by the same group (Semmens et al” 1983) found SHBG is 
independently, directly associated with HDL-C in men and women and suggested 
that there is an inverse correlation between unbound endogenous testosterone and 
HDL-C. Plasma estradiol levels are not significantly associated with HDL-C in 
either sex. Stefanick and co-workers (1987) showed that plasma total testosterone 
levels have significantly inverse associations with HDL cholesterol and HDL2 
mass concentrations, and a significant negative relationship was found between 
SHBG and triglycerides, while the plasma E2 level was found independently, 
inversely related to total and LDL-cholesterol. There is no clear relationship 
between E 2 / T and HDL-C after adjusting for other confounders. 
However, the data of other workers pursuing this subject showed a 
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different result and suggested a direct relationship between free testosterone and 
HDL-C (Heller et al” 1983). Lichtenstein et al. (1987) proposed that the serum E〗 
levels are associated directly with HDL, but the relationship disappeared after 
adjusting for the testosterone and insulin level, whereas the serum testosterone 
levels are associated directly with HDL and inversely with triglyceride. The 
associations persist after adjusting for age, BMI, insulin and/or triglyceride. 
Kiel et al. (1989) presented a negative result showing that there is no 
association between total- or free- testosterone and HDL-C, whereas a consistently 
positive correlation exists between total estradiol or calculated free estradiol and 
both total cholesterol and HDL-C. In addition, they proposed that there is a 
complex interaction between endogenous testosterone and estradiol with respect to 
total cholesterol. Khaw and Barrett-Connor (1991) carried out a community cohort 
study from which they concluded that HDL-C levels are positively, and VLDL-C 
levels negatively associated with serum testosterone, after adjusting for 
confounders. Serum E〗levels are positively correlated with LDL-C. However, in 
the Multiple Risk Factor Intervention Trial (MRFIT) Dai et al. (1981) 
demonstrated an inverse relation between plasma estradiol levels and LDL-C 
concentration in spite of a consistent direct relation between plasma testosterone 
and HDL-C concentrations in both cross-sectional and longitudinal analyses among 
men. 
Since unbound rather than SHBG-bound sex hormones are bioavailable 
(Anderson, 1974), SHBG in circulation functions as a modulator of sex-hormone 
delivery to tissue (Nestler, 1993). Adiposity has effects on SHBG concentrations 
and sex-hormone levels (Bray, 1989). Furthermore, obesity is an important source 
of variation in lipoprotein-lipids levels and profiles. There may be associations 
between endogenous sex hormones and lipoprotein-lipids when these potential 
confounders are accounted for. 
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Chapter III. Materials and Methods 
III.l. Subjects and Sampling Methods 
A total of 46 apparently healthy Chinese men, aged 19 to 53 years, were 
recruited for the study of the association between sex hormones and lipoproteins. 
Due to the intraindividual variability of lipoprotein-lipids and the diurnal 
oscillations of sex hormones, sampling was carried out on two occasions to try to 
account for some of this variation. 24 hr urine samples were collected twice 
(22±10 days apart), and fasting blood samples were drawn the following 
morning between 8:30 and 10:00 am. after fasting from 9 pm the night before, 
19 土 8 days apart. Lipoprotein-lipids, apolipoproteins, sex hormones, and sex 
hormone-binding globulin in serum samples were determined. Serum testosterone 
and estradiol concentrations and urinary unconjugated and conjugated testosterone 
and estradiol together with unconjugated (free) Cortisol were also determined. 
Each determination was performed in duplicate. 
No subject was taking drugs or medications or was engaged in any 
unusual physical activity prior to blood taking. The degree of adiposity expressed 
as body mass index (BMI) was determined as weight/height^ (kg/m^). Body fat 
distribution was assessed as the waist to hip ratio (WHR), by measuring minimal 
waist and maximal hip girth. Alcohol consumption, and cigarette consumption 
were recorded. 
Blood was drawn by venipuncture of the antecubital vein in the seated 
position, with a 21-gauge needle attached to a 20 ml plastic syringe and collected 
without any anticoagulant into two plastic tubes. After standing at room 
temperature for 1 to 2 hours, the serum was separated by centrifugation (l,500x 
g, 5 min, 4°C). The serum was removed and aliquots were prepared in small, 
screw-capped, plastic vials. Al l vials were snap-frozen in liquid nitrogen 
immediately and then stored at -70°C. Venus blood collected without 
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anticoagulant was processed without undue delay to remove RBC, since red 
cells at room temperature wil l alter plasma concentration of active steroid 
hormones; they can degrade estradiol to estrone, and Cortisol to cortisone as 
well as adsorb testosterone (Tietz、1986). 
An aliquot of the serum sample was used for gamma glutamyl transferase 
(yGT) determination as a marker for excessive alcohol consumption, and for 
serum albumin for the purpose of calculating unbound free hormones. 
Urine was collected in plastic urine bottles without any preservatives 
added. After collection was finished urine samples were dispensed into glass 
tubes (13 X 100mm) in aliquots of 6 to 8 ml, capped tightly and stored at -70°C 
without any delay. Urinary creatinine was assayed in parallel with urinary 
hormones (Gerlo et al” 1991) to ensure the completeness of the 24-hr urinary 
collection. Urinary collections with <0.5 g of creatinine were considered 
incomplete 24-hr collections and were excluded. No specimen had a creatinine of 
<0.5g and therefore all were included. 
The following biochemical analyses was generally performed in duplicate 
to reduce the effect of analytical variation. 
IIL2. Quantitation of serum lipoprotein-lipids 
IIL2.1 Determination of cholesterol and triglyceride 
Total plasma cholesterol and triglyceride were determined enzymatically 
on a Cobas Bio analyzer (Roche Diagnostics, MontClair, New Jersey) using 2 
point-standards (8.68 mmol/L and 4.34 mmol/L). The lower standard was 
derived by diluting stock (8.68 mmol/L) with 4% bovine albumin in aqueous 
solution. 
The principle of cholesterol analysis involves the enzymatic hydrolysis of 
cholesterol ester to free cholesterol and fatty acids by cholesterol esterase and 
enzymatic oxidative conversion of free cholesterol to cholesterol-4-ene-3-one and 
10 
30 
hydrogen peroxide by cholesterol oxidase. The hydrogen peroxide formed is then 
quantified by reaction with phenol and 4-aminophenazone in the presence of 
peroxidase to form an o-quinoneimine, which was measured photometrically at 
the wave length 520nm. 
The principle of triglyceride analysis is based on four separate reactions: 
(1) enzymatic hydrolysis of triglycerides to glycerol and free fatty acid by lipase; 
(2) enzymatic conversion of glycerol and ATP to glycerol-3-phosphate and ADP 
by glycerol kinase; (3) oxidative conversion of glycerol-3-phosphate to di-
hydroxy acetone phosphate and hydrogen peroxide by glycerol phosphate 
oxidase, and (4) conversion of the chromogen by hydrogen peroxide to 
quinoneimine using peroxidase, which can be measured photometrically at the 
wave length of 520nm. 
The reagents were from Roche Diagnostic System (Basel, Switzland). 
Unimate 5 (lot S2832) and Unimate 5 (lot S1031) were used for cholesterol and 
triglyceride respectively, and Calibrator (Lot 1542) was used for both cholesterol 
and triglyceride. Ciba Coming ch-B，Lot N020103 and lot L025103, were used 
for quality control throughout all analyses. 
A listing of parameter settings is attached as Appendix i. The intra- and 
inter-batch variations of controls at two different levels for cholesterol and 
triglyceride are summarized in Table III.2.1.A and Table in.2.1.B. 
Table 111,2,1, A. Intra-assay variations for cholesterol and triglyceride by enzymatic 
determination on Cobas Bio automatic analyzer using Unimate 5 reagent (Roche 
Dignostic System) 
Controls (mmol/L) No. of within- Observed value Bias % CV% 
Parameter (Mean 土 SD> assay (Mean 土 SD> 
Cholesterol 3.6 士 0.5* 10 ~ ± 0 . 0 4 11.1 1.26 
10 2.64 土0.03 2.2 1.31 
Triglyceride 0.9 士 0.1** 10 0.96 士 0.01 6.6 1.1 
1.8 士 1 0 1.80士0.03 I 0 1.9 
*,** QCSNORASY (Ciba Coming, lot no. 020103) 
QCSABNASY (Ciba Coming, lot no. 025103) 
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Table IIL2J,B. Inter -assay variations for cholesterol and triglyceride by euTymatic 
determination on Cobas Bio automatic analyzer using Unimate 5 reagent system 
(RocheDiagnostic System) 
Controls (mmol/L)no. of between Observed value Bias % C\% 
Parameter (Mean 士 SD> assay (Mean 士 SD> 
Cholesterol 一 3.6土0.5* 8 3.35土0.15 6.9 ^ 
2 . 7 士 8 2.58+0.16 4.4 6 
Triglyceride 0.9 士 0.1** 8 0.94±0.03 4 l i 
I 8 I 1.95土0.08 I 8 Li:2 
*,*» QCSNORASY (Ciba Coming, lot no. 020103) 
#，## QCSABNASY (Ciba Coming, lot no. 025103) 
IIL2.2. Determination of HDL-Cholesterol and its subfractions 
Lipoprotein concentrations in serum are usually measured in terms of their 
cholesterol content. HDL-Cholesterol and its subfractions were determined by 
measuring cholesterol in the supernatant subsequent to dual precipitation with the 
precipitating agent--MgCl2/Dextran sulfate (Warnick et al., 1982; Bachorik and 
Albers, 1986). The first precipitation was to remove apoB-containing lipoproteins 
by mixing serum samples (500 well with Reagent A (50 [il) and letting it 
stand at room temperature for 15 min. The precipitate was then removed by 
centrifugation at 2,000x g for 15 min, and the cholesterol in the supernatant 
determined. The subsequent precipitation was achieved by adding Reagent B (25 
^1) to the HDL-C supernatant (250 |il) at room temperature and letting it stand 
for 20 min. HDL3-C was then determined in the supernatant. Appropriate 
dilution factors were applied for each step in order to get the final 
concentrations. The reagent A is a mixture of 1% dextran sulfate (50,000 MW) 
and MgCl2 (0.5 mol/L). The reagent B is a mixture of 1% dextran sulfate and 
MgCl2 (1.5 mol/L). 
HDL2-cholesterol concentrations were calculated by subtracting HDL3-
cholesterol from the total HDL-cholesterol. 
The reagents used for cholesterol determination were similar to those for 
total serum cholesterol, except for a lower level of 3-point standards (0.54, 1.08, 
2 17 mmol/L respectively), which were obtained by serial dilution from a stock 
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calibrator (8.64 mmol/L) with 4% bovine albumin in aqueous solution. Also, 
sample volumes were increased from 5 fxl to 20 fi l for better precision and 
recovery. QCsNorasy (Ciba Coming lot no.N020103) was used for quality 
control. After precipitation with MgCl2/Dextran sulfate, the coefficient of intra-
assay coefficient of variation for using this QC material was 1.6%, and for 
interassay was 8.4% (Table m.2.2). 
Table III.2.2. Intra- and inter-assay variation for HDL-cholesterol 
QC for HDL assay (QCsNorASY)* Within-assay (n=12) Between-assay (n=12) 
i 
Expected value (Mean±SD) (mmol/L) 0.9±0.2 0.9士0.2 
I Obseired value (Mean±SD)(mmol/L) 0.89士0.014 0.88士0.07 一 
Bias % 1 2 
CV% 1-6 8.4 
• Ciba Coming (lot no.020103) 
IIL2.3. Determination of VLDL-C and LDL-C 
These values were derived by applying the formula of Friedewald et aU 
(1972). This formula is based on two assumptions: (i) that most of the fasting 
triglyceride in plasma is located in VLDL (ii) that the mass ratio of 
triglyceridexholesterol in VLDL is 5:1 (molar ratio 2.19:1). This is true except 
in type I I I hyperlipoproteinaemia or in the presence of marked 
hypertriglyceridaemia (triglyceride > 5.Ommol/L). Thus, the value (in mmol/L) 
of VLDL-C is calculated by dividing triglyceride by 2.2 and LDL-C is obtained 
from the equation : 
LDL-C = Total cholesterol - HDL-cholesterol - Triglyceride/2.2 (Al l in 
mmol/L). 




IIL2.4.1. Determination of Apolipoproteins A-I and B 
ApoA-I and apoB levels were measured by immunonephelometry using 
the Beckman Array nephelometer (Beckman Instruments, Brea, Calif.). The 
reagents used were from Beckman: ApoA (lot no. M010221) and ApoB (lot no. 
M011173). The assay is calibrated against Beckman calibrator (Beckman lot 
M105114), and controlled with a control serum from Beckman (lot M109227). 
The rate nephelometer measures the peak rate of changes in intensity of 
light as it is scattered by particles which are formed by the immunoprecipitin 
reaction of a specific antibody and the specific antigen in suspension. The 
coefficients of variation within run and between runs were < 5% and < 8%, 
respectively. 
IIL2.4.2, Determination of Lipoprotein (a) 
Lp(a) was measured by the SPQ test system for Lp(a) (Incstar Co., 
Stillwater, Minn. USA) on a Cobas Bio automatic analyzer. The principle is 
based on immunoturbidimetric analysis. The antigen-antibody reaction wi l l 
produce turbidity in the mixture and thus increase the amount of light absorbed 
by the solution. After an incubation period lasting approximately 10 min, the 
absorbance of the solution is measured at a wavelength of 340 nm. A calibration 
curve is generated by assaying a series of standards with known concentrations of 
lipoprotein (a) and by using the data reduction capability of the Cobas Bio (Dens 
plot). Concentrations for the control and samples are interpolated from the 
calibration curve. The lowest detection limit of the standard curve is 55 mg/L. 
The coefficients of variation within run and between runs were < 3% and < 
9%, respectively. 
HI. 3. Quantitative determination of sex hormones 
As there are no suitable commercial immunoassays available for the 
determination of very low levels of unconjugated testosterone and unconjugated 
33 
34 
estradiol in the urine, sensitive in-house radioimmunoassays for the two 
hormones were set up. 
111.3.1. For urinary unconjugated and serum total testosterone 
Anti-testosterone serum was raised in the rabbit to the testosterone-3-(o-
carboxy methyl) oxime-BSA conjugate. It was a gift to Dr. N. S. Panesar from 
the Division of Steroid Encocrinology, Leeds University, England and had been 
kept in our laboratory since 1985. 
[1,2,6,7-^H]-Testosterone (Amersham code TRK.402, batch 58，1985) 
was kindly provided by Dr. N. S. Panesar. It needed to be purified before use 
(See III.3.1.1). After this batch of the tracer ran out a new batch of [1,2,6,7- H]-
Testosterone (Amersham code TRK.402, batch 85, 1992) was purchased from 
Amersham Co. England, which was used without further purification. A l l tracers 
were diluted with assay buffer to give an activity of 10,000 dpm/O.l m l . 
A series of non-radioactive testosterone (Sigma T-1500) solutions was 
made up in absolute ethanol so that each lOOjd contained 0，43.4,.86.8, 173.6, 
347.2，694.4 fmol of testosterone respectively. These solutions served as 
standards in RIA and the ethanol was evaporated before assay. 
Phosphate buffer (0.05 mol/L) containing 0.1 % gelatin and 0.01 % sodium 
azide with pH adjusted to 7.4 was used for diluting anti-testosterone serum and 
tracer throughout. Dextran-coated charcoal (0.5%) which contains activated 
charcoal (Sigma, no.C-5385) and dextran ( BDH chemical Ltd., Poole, England) 
was used for removing the excess free testosterone during assay. The charcoal 
(2.5g) and dextran (0.25g) were mixed in 500 ml phosphate buffer on a magnetic 
stirrer for one hour. After mixing, the preparation was stored at 4°C. 
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III, 3.1,1 Experimental Procedures 
Determination of the optimal antibody titre 
An antiserum dilution curve (Fig. 1) was obtained by incubation of a fixed 
amount of tracer ligand (0.1 ml) with 0.1 ml of various dilutions of the antiserum 
with or without unlabelled testosterone added. Usually the highest concentration 
of the standard was used. The optimal titre could be determined by the largest 
displacement of these two curves near 50%-bound of radioactivity. In practice 
1:8000 and 1:16,000 dilutions were used. 
Establishment of a standard curve and quality controls 
Preparation of standards 
Starting with Img/ml of non-radioactive testosterone in absolute ethanol 
as a stock, serial dilutions were made with absolute ethanol to give a final 
concentration of 2.0 ng/ml which was the highest standard (694.4 finol/lOOjil). 
From 2.0 ng/ml, doubling dilutions with absolute ethanol were made to get 
solutions of 347.2，173.6，86.8，and 43.4 fmol per lOO/xl. Absolute ethanol was 
used as a zero standard. A l l standards were kept separately in screw-capped 
glass vials and stored at -20。C to minimize evaporation. The standards were 
brought back to room temperature before use. 
The typical standard curve for testosterone was obtained by incubating a 
known concentration of antiserum, standards, and a fixed amount of ^H-
testosterone (10,000 dpm) at 4。C for 16 hours The free (unbound) testosterone 
was adsorbed by addition of 0.5 ml cold dextran-coated charcoal and 
centrifugation at 3,500 g for 15 min at 4°C. The supernatant was decanted into a 
vial containing 5 ml scintillation cocktail and radioactivity determined in a p-
spectrometer. The %bound radioactivity was calculated, and plotted as %bound 
of radioactivity vs testosterone concentration (Fig.2). 
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Fig. 1. Testosterone antiserum dilution curve 
A fixed amount oftritiated testosterone (^H-testosterone) (10,000 dpm/O.lml) was incubated 
at 4°C with a fixed amount (0.1ml) of various dilutions of rabbit anti-testosterone serum with 
or without cold testosterone (200 pg) added. After an incubation period of 16 hours, the 
excess free triatiated testosterone was absorbed by dextran-coated charcoal. 
• - • curve obtained with cold testosterone added. • _ • curve obtained without any cold 
testosterone. The optimal titre of antiserum could be determined by the largest displacement 
from these two curves near 50% bound. 
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Purification of radioactively-labelled -H-testosterone 
The purity of the tracer could be restored after long storage by thin-layer 
chromatography. Half a sheet of aluminium TLC sheet precoated with silica gel 
60 F254 (size: 20 x20cm, layer thickness 0.22 mm) (Merck Art.5554) was used. 
Before use, the sheet was reactivated at 110°C for 30 mins. 10/xl of 1 ixoHiiX of 
^H-testosterone and lOptl of 1 mg/ml non-radioactive testosterone were run 
together vertically in a TLC tank pre-saturated with the solvent system of 
cyclohexaneiethylacetate (60:40) at room temperature for 135 min until the 
solvent reached one centimeter from the top of the sheet. The chromatogram was 
air-dried in a ftimehood. The dried chromatogram was then examined under UV 
light. Non-radioactive testosterone fluoresces under light of 265mn and served as 
a marker. The average Rf for testosterone after three determinations was 0.38. 
(Rf is defined as the ratio of the distance the sample moved from the origin to the 
distance the solvent moved from the origin in the chromatogram.). 
Once the position of ^H-testosterone was determined, it could be cut out 
and eluted with a known amount of absolute ethanol. The eluent was centrifuged 
to remove the silica gel and 0.1 ml was transferred into a scintillation counting 
vial containing 2ml of scintillation fluid, and the radioactivity counted. The eluent 
was evaporated under a nitrogen stream and redispersed in a known amount of 
phosphate buffer. This was used as a stock solution. Before use, it was diluted 
with phosphate buffer to give the desired radioactivity. 
Preparation of charcoal- stripped ur im as zem ealihmtQr (blank) 
Activated charcoal and an aliquot of urine (or plasma) (lOg per 100ml) 
were stirred at 4。C in a cold room overnight (Chard, 1990). For charcoal-
stripped urine, the mixture was filtered through Whatman No. l filter paper 
twice, and then through a Millipore 0.22/x filter twice to remove all the charcoal 
particles. For charcoal- stripped plasma, it was necessary to centrifuge the 
mixture twice at high speed (10,000 Xg) for one hour before passing through the 
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Millipore filter, as the charcoal particles carried by the plasma passed through 
Whatman No. l filter paper. The final clear filtrate was then prepared in aliquots 
and stored at -70°C. 
Preparation of spiked urine or plasma 
The testosterone stock solution (Img/ml) was diluted 1:1000 to obtain a 
final concentration of 1 jug/ml. 100 /xl of this solution was added to 100 ml 
stripped urine (or plasma) to make 347.2 fmol/100 | i l spiked urine (or plasma). 
The subsequent 173.6 ftnol/lOOjil and 86.8 ftnol/100 spiked urine or plasma 
solutions were obtained by doubling dilution of the 347.2 finol/100 | i l solution 
with charcoal-stripped zero calibrator. A l l spiked urine or plasma samples were 
dispensed in aliquots of 0.3ml (assay volume) in borosilicate glass tubes 
(100x13mm)，capped tightly and stored at -70°C. 
Preparation of samples for EIA 
For urine samples, usually 1.5 ml of the clear supernatant was used after 
the crude urine was centrifuged at a speed of l,500g for five minutes. 
Diethylether (3ml) was added to the urine sample in a 100 x13mm borosilicate 
glass tube. The extraction was carried out by vortexing vigorously on a 
multitube vortexer at speed 4 for 60 seconds, three times. The organic and 
aqueous phases were then separated by freezing the aqueous phase at -70°C for 
20 mins. One ml of the upper layer (ether extract) was transferred to a 10x75 
mm glass tube (in duplicate) for RIA. The urine volume was reduced i f the 
concentration was too high. 
Serum samples were diluted 1:10 with 0.9% saline before extraction. 0.3 
ml of the diluted serum was extracted with 3 ml of diethylether. One ml of the 




Al l standards, samples, and controls were processed identically. Two 
charcoal-stripped blank tubes were also included, not only for monitoring the 
binding of antiserum at zero concentration but also for monitoring the non-
specific binding in buffer. The protocol was as follows: 
1). lOxTSmm glass tubes were labelled for non-specific binding, blank, controls 
and samples in duplicate, and standards in triplicate. 
2). 1 ml of the ether extract or 0.1 ml of standards were transferred to each 
corresponding glass tube. 
3). 0.1 ml of absolute ethanol was added to all tubes of samples and controls, and 
1 ml of diethylether was added to all tubes containing standards. 
4). The tubes were evaporated in vacuum oven at 40°C under a pressure of 
30 mmHg for 45 to 60 minutes. 
5). 0.1 ml of antiserum was added to all tubes except tubes for non-specific 
binding which had 0.1 ml buffer added instead and the tube vortex mixed at 
speed 3 for 20 seconds on a multitube vortexer. 
6). 0.1 ml of tracer was added to all tubes and the tubes vortex mixed at speed 
3 for 20 seconds. 
7). Incubation was performed at 4°C for 16 hours. 
8). 500 /xl of cold dextran-coated charcoal was added to and tubes vortex-mixed 
gently at speed 2 for 20 seconds. This step was performed on ice. A l l tubes 
were standing on ice for 15 mins to reach equilibrium after the dextran-coated 
charcoal was added to the first tube. 
9). The tubes were centrifuged for 15 mins. at 4。C，x3,500g. 
10). The supernatant was decanted into a scintillation counting vial containing 5 





The standard curve was plotted as % bound of total ^H-testosterone 
radioactivity vs concentration of the standard. The concentration of testosterone 
in the unknown sample was interpolated from the standard curve, and the results 
were corrected for the dilution factor. 
IIL3.1.2. Characteristics of the radioimmunoassay for testosterone 
Sensitivity 
The sensitivity (limit of detection) of an assay is usually defined as twice 
the standard deviation of the blank determination on a standard curve (Haning et 
al” 1979; Chard, 1990). 
Ten replicates of zero standard (expressed as %bound of total count) were 
used to calculate the mean of counts bound and the standard deviation (i.e. 39.8 
+ / - 3.3%). A new standard curve was also constructed by plotting the mean of 
counts bound of ten replicates of all standards as the function of testosterone 
concentration. As shown in Fig.2, the mean plus/minus two S.D. (33-46% 
bound) is considered as the confidence limits of the zero standard while the mean 
of the zero standard minus two S.D. (40-33% bound), read as concentration 
(i.e. 12 pg or 41.6 fmol per 0.1 ml ethanol), is the minimum detection limit of 
this standard curve. Also the mean and the standard deviation of the 
corresponding 10 replicates of charcoal-stripped urine blank (which is 41 + / -
3.5%) were calculated. The corresponding "limit of detection" is about 10 pg or 
34.7 ftnol per 0.1ml of biological fluid which is slightly lower than that of the 
zero standard of pure ethanol. This slight difference is probably due to a matrix 
effect, which could be overcome by increasing the levels of sex hormones in the 
assayed biological fluids to well above the minimal detection limit. In this study 
the levels of sex hormones in assayed biological fluids were many times greater 
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Fig. 2. The lowest detection limit of the standard curve for testosterone 
A new standard curve of ten RIA replicates was constructed by plotting the mean counts (as 
% bound) of all standards in these ten replicates as the ftinction of testosterone concentration 
(pg/O.lml). The confidence limit (mean+2SD) to the zero standard estimate was 46.4%, 
while the lowest detection limit of this standard curve (mean-2SD) read as concentration was 
about 12 pg/O.lml (at 33.2% bound). Similarly the lowest detection limit using this standard 
curve by the zero control blank (charcoal-stripped urine) was also calculated, which was 
about 10 pg/0.1ml (at 33.6% bound), whereas the confidence limit to the zero blank estimate 
(mean+2SD) was 47.6%. The lowest detection limit of the zero blank in biological fluid is 2 
pg lower than that of pure ethanol. In this case, the slight difference of lowest detection limit 
in these two different systems could be overcome by increasing the levels of sex hormone in 
assayed biological fluids well above the minimal detection limit. 
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than the minimal detection limit [usually between 50-100 pg (173.6-347.2 
fmoiyO.lml biological fluid], and the lowest detection limit was not a limitation 
in the assay (Chard, 1990). 
Precision studies 
Within- and between- batch imprecigipng 
The spiked charcoal-stripped urine with high (347.2 fmol/tube), medium 
(173.6 finol/tube), or low (86.8 fmol/tube) values of testosterone were used to 
determine within- and between- batch imprecisions. 14-17 sets and 30-31 sets of 
spiked samples were used for within- and between-batch assays respectively. 
Between batches, the spiked charcoal-stripped urines at 347.2 fmol/tube, 
173.6 fmol/tube, and 86.8 fmol/tube respectively were spaced out between 
samples and always processed in the same way as that of samples. The variations 
were noted and summarized in Table III.3.1.2.A and Table III.3.1.2.B. 
Table IIL3J.2.A. Within-run variation for assay of testosterone added to charcoal-
stripped urine. 
Volume of charcoal-
Testosterone added stripped urine blank N CV % 
fmol (pg) 
347.2 (100) 0.1ml 一 17 
173.6 (50) — 0.1ml 14 
_ 86.8(25) 0.1ml 17 7.3 
Table IIL3.1.2.B. Between-run variation of assays of testosterone added to charcoal-
stripped urine 
Volume of charcoal-
Testosterone added stripped urine blank N CV % 
fmol (pg) 
347.2 (100) 0.1ml ^ L ^ 
173.6 (50) 0.1ml ^ 7.38 




The recoveries of spiked control urines at different concentrations were 
calculated by the formula: %Recovery = Mean of the testosterone measured 
-5-Total testosterone spiked Xl00%. The results were summarized in Table 
III.3.1.2.C. 
Table IIL3.1.2.C. The recoveries of known amounts of testosterone added to charcoal-
stripped urine, between immunoassays. 
Testosterone spiked Testosterone N Recovery Rate % 
fmol (pg) measured (Mean 
士 SEM) pg 
347.2 (100) 一 101.94 士 1.42 17 101.94 
173 .6 (50) 一 53.85 士 1.09 14 108 一 
86.8 (25) 27 土 0.48 17 108 
Test of linearity 
For this purpose, a urine pool which showed a low level of testosterone 
was used. Urine samples were prepared in aliquots of 0.3，0.6, 0.9 and 1.2 ml in 
glass tubes which were respectively extracted with a fixed amount (3ml) of 
diethylether. 0.1 ml of each ether extract was used for RIA. The amount of 
steroid recovered showed a linear relationship with urine volume (Fig. 3). 
Comparison with another procedure 
The in-house testosterone assay was compared with the commercial assay 
(DPC) using the sera from the 22 healthy men. The correlation between these two 
methods was good (r=0.933，p=0.000); RIAinhouse=l-19x RIAdpc+0.02 
(Fig.4). The value obtained by the "in-house" assay is higher than that of the 
DPC commercial kit, which may be due to the different specificities of the two 
antisera, or to small differences in calibration. 
In view of the agreement between these two methods, the decision to 
assay serum testosterone with the in-house assay method was therefore made for 




Cross reactivity of the antiserum 
Specificity is a characteristic of immunoassay. However, some biological 
materials may interfere in the radioimmunoassay by competing with the ligand at 
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Fig. 4. Correlation of results of serum testosterone in 22 apparently healthy 
Chinese men，which were determined by "in-house" RIA (y axis) and DPC 
RIA kit (X axis), Y=1.19 X + 0.02 (r=0.933, p=0.0000). The value obtained by ” in-
house" RIA is higher than that by DPC kit. (bottom). Another way to express the correlation 
(top) was by plotting the difference in values between the two methods against their mean, 
with discrepancies of up to 8 nmol/L. Mean=3.23 nmol/L and SD=2.4 nmol/L. A subject 
with a extremely high value was excluded. The discrepancies might be due to different 
standardization of the method and the specificity of the antiserum prepared. 
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the binding site of the antibody due to their physicochemical resemblance in 
structure . 
Cross-reactivity of identifiable materials to a given antiserum is one of the 
methods to judge the specificity of the antiserum. The sources of structurally 
similar compounds are as follows: 
1. d-aldosterone (4-pregnen-18-al-llB,21-diol-3,20-dione), Sigma catalogue no. 
A-6628, Lot no. 23F-4025, FW 360.5 
2. Progesterone (4-pregnene-3,20-dione), Sigma cat. no. P-0130, Lot no. 73F-
0198，FW 314.5 
3. 17-hydroxy-progesterone (A4-pregnene-17-ol-3,20-dione), Sigma cat. no. H-
5752, Lot no. 83F-0458, FW 330.4 
4. Hydrocortisone (Cortisol), Sigma cat. no. H-4001, Lot no. 14F-0064, FW 
362.5 
5. Corticosterone (A^-pregnene-llB, 21-diol-3，20-dione) Sigma cat. no. A- 9630， 
Lot no. 18C-0226, FW 284.4 
6. 5-DHT (A5-androstan-17B-ol-3-one), Sigma cat. no. A-8380, Lot no. 14F-
0469，FW 290.4 
7. 6-Estradiol, Sigma cat. no. E-8875, Lot no. 34F-0540, MW 272.4. 
Procedure 
a. Serial dilutions of a stock solution (1 mg/ml) in absolute ethanol from all 
compounds in question were made as follows: 100 ng/ml, 50 ng/ml, 25 ng/ml, 
12.5 ng/ml, 6.25 ng/ml, ....up to 0.095 ng/ml. 
b. 0.1 ml of the diluted solution was put through RIA along with testosterone 
standards. 
c. %bound vs concentration of testosterone was plotted on semi-log graph paper. 
Percent cross-reaction at 50% displacement of testosterone standard curve 
was calculated from the formula: 10 
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Concentration of Testosterone (50% bound) 
% Cross reactivity x 100 
Concentration of Cross- reactant (50% bound) 
The cross-reactivity of the testosterone antiserum with other adrenal steroids 
such as d-aldosterone, 17-OH-progesterone, hydrocortisone (Cortisol), 
corticosterone, and 17B-estradiol was not traceable (with no reaction up to each 
mass of 10 ng/O.lml) but there was 40% cross reaction with 5a-DHT, 0.27% 
with androstenedione and 0.015% with progesterone. The data are summarized in 
Table ffl.3.1.2.D. 
Table IIL3.1,2,D, Cross reactivity of some naturally occurring steroids with 
testosterone antiserum 
Compound Molecular % Cross Rx at 50% Molar % 
weight displacement cross reaction 
Testosterone — 288.4 IW 100 
5a-DHT 一 290.4 £2 4 0 ^ 
Androstenedion — 286.4 
Progesterone “ 314.5 0.014 0.015 
d-aldosterone 360.5 ； : 
17-OH-progesterone 330.4 - ： 
Hydrocortisone 362.5 - : 
Corticosterone 346.5 - ： 
17P-estradiol 272.4 - I -
Most (at least 70%) of plasma DHT in males is from testosterone and DHT is a 
form of potent metabolite of testosterone at the tissue level (Lipsett, 1986). The 
production rate of DHT in males is less than 5% of that of testosterone (Bardin, 
1986). DHT has much higher (about three times) binding affinity to SHBG 
than that of testosterone (Lipsett, 1986). In view of these arguments one can 
assume that there would be very little cross-reaction from DHT in the assay of 
urinary and plasma testosterone. 
111.3.2 For urinary total testosterone 
Most of the metabolites of testosterone are in the form of glucuronide 
and/or sulfate conjugates which are more polar and soluble in water and therefore 
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excreted in the urine by glomerular filtration. For determination of urinary total 
testosterone, therefore, it is necessary to hydrolyze the conjugates with enzyme or 
acid before extraction and quantitation. The simplest method is by acid 
hydrolysis. However, acid hydrolysis may introduce the so called "non-specific 
non-specificity" (Chard, 1990) effect to the antiserum, resulting in interference 
and non-reproducibility. A traditional way to eliminate non-specific non-
specificity is to dilute the sample. From several trials both with the "in house" 
and DPC RIAs and from the example of the protocols for urinary free Cortisol 
and urinary total testosterone by DPC reagent kits, it was found that diluting the 
hydrolyzates 1:25 with charcoal-stripped urine prior to extraction could overcome 
this problem. The protocol developed for urinary total testosterone assay was as 
follows: 
1. Acid hydrolysis: To 1 ml urine sample, 0.2 ml of 12N HCL was added at 
100°C in a boiling water bath for 15 mins. 
2. The resulting acid hydrolyzate was diluted 1:25 with charcoal-stripped urine. 
3. Usually 0.3-0.6 ml of the diluted hydrolyzate (reduced volume i f the 
i 
concentration was too high) was extracted with 3ml diethylether. 1ml of the ether 
extract was used for RIA following the same procedure as that described in 
section in.3.1.1. 
Test of linearity and recovery 
To 1 ml of spiked urine (containing testosterone 5 ng/ml), 0.2 ml of 12N 
HCL was added and hydrolyzed in a boiling water bath for 15 mins. A charcoal-
stripped urine blank was treated the same way. The resulting acid hydrolyzate 
was diluted 1:25 with charcoal-stripped urine. 0.3 ml, 0.6 ml, 0.9 ml, and 1.2 ml 
of the diluted hydrolyzate and the blank were extracted respectively with 3 ml of 
diethylether. 1 ml of the ether extract was used for RIA. As shown in Fig.S 
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volume of diluted urine hydrolyzate with a recovery of 91.3%. 
III. 3.3. For urinary unconjugated and serum total 17fi-Estradiol 
Lyophilized antiserum for 17p-E2 was purchased from Shanghai Institute 
of Endocrinology, Shanghai, China. According to the information provided, this 
antiserum was raised in a rabbit against a 17p-estradiol-6-(carboxymethyl)-oxime-
BSA conjugate. It is slightly cross-reactive to ITa-Ej (0.7%), to estrone & estriol 
(about 1%) and to testosterone (0.1%) (Prof. Mi , Shanghai Institute of 
Endocrinology, personal communication). 
[2,4,6,7,16,17-'H]-estradiol (Amersham code TRK587, batch 114) was 
used as a stock. 20,000 dpm/100 \il of radioactivity was obtained by diluting the 
stock with phosphate buffer. The buffer solution and dextran-coated charcoal 
used for E2 RIA were identical to those for testosterone described previously. 
A series of aliquots of non-radioactive P-estradiol (Sigma Cat. E-8875, 
Lot 34F-0540) was made up in absolute ethanol so that 100 lA contained 0, 4.6, 
9.2, 18.4, 36.7, 73.4, and 146.9 fmol of estradiol, respectively. These solutions 
were used as standards and the ethanol was evaporated before assay. 
IIL3.3.1 Experimental procedure 
Determination of the optimal antibody titre 
Antiserum dilution curves (Fig.6) were constructed by incubation of a 
fixed amount of tracer ligand (20,000 dpm/O.lml) with 100 f i l of various 
dilutions of the antiserum with and without standard (36.72 fmol/O.lml) added. 
The optimal concentration was determined by the largest displacement from these 
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Fig. 6. The dilution curves of antiserum to 1 Jfi-estradiol 
0 - 0 without addition of cold E^. • - • with cold E^  (10 pg) added. A fixed amount of 
^H-np-Ej (20,000 dpm) was incubated at 4�C with a fixed amount of various dilutions of 
rabbit anti-17p-E, serum with or without cold 17p-E, (10 pg). After an incubation period of 
20 hrs. the excess free ^H- np-E^ was absorbed by dextran-coated charcoal. The added cold 
E2 competed with ^H-E^  at the binding site of antiserum, therefore, with less % bound of 
radioactivity the curve (• - •) was shifted to left. The optimal titre of antiserum could be 
determined by the largest displacement from these two curves. 
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two curves. In practice, a 1:40,000 dilution was used thoughout the experiments. 
The detailed protocol is basically the same as that described for 
testosterone in sections III.3.1.1 except that the antiserum was serially diluted to 
1:1,000，1:2,000, 1:4,000 ....up to 1:128,000 from the original dilution and the 
incubation period was prolonged to 20 hours. 
Establishment of a standard curve and quality controls 
Preparation of standards 
Starting with 1 mg/ml of non-radioactive 17P-E2 in absolute ethanol as a 
stock, serial dilutions were made by diluting the stock solution with absolute 
ethanol to make Ing/ml as a sub-stock. The highest standard, 146.9 finol/O.lml 
was prepared from 10 ml of 1 ng/ml, which was evaporated under a nitrogen 
stream and then redispersed into 25ml of absolute ethanol in a glass vial. The 
subsequent series of standards (73.4 fmol/O.lml, 36.7 fitnol/O.lml, 18.4 
fmol/O.lml, 9.2 ftnol/O.lml, and 4.6 ftnol/O.lml) were achieved by doubling 
dilution from 146.9 finol/O.lml. Absolute ethanol was used as zero standard. 
A l l standards were stored in glass vials with caps tightly screwed and kept 
in -20°C. A l l standards were brought back to room temperature before use. 
Preparation of tracer ^H-estradiol and construction of a Standard carY£ 
^H-E2 was diluted directly from the reagent bottle with phosphate buffer. 
About 20,000 dpm per tube were used throughout all assays. 
A typical standard curve for E〗RIA is shown as Fig.7. The detailed 
protocol was similar to that for testosterone, except the incubation period was 
prolonged to 20 hours which allowed the very minute amount of E2, antiserum, 
and tracer to reach equilibrium completely at 4°C. 
Preparation of spiked control urine QT plasnm 
The base for spiked standards which served as controls was charcoal-
stripped urine or plasma as described in Section I I I . 3.1.1. 
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E2 sub-stock solution (1 ng/ml in absolute ethanol) was used for this 
purpose. The procedure is briefly described below: 
4 ml of (1 ng/ml) substock solution was placed in a glass vial, dried under 
a nitrogen stream and then redispensed in 20 ml of charcoal- stripped urine or 
plasma. This gave a 73.4 fmol/O.lml control solution which was double diluted 
to obtain 36.7 and 9.2 fmol standards. A l l spiked urines or plasmas were 
dispensed into 100 x13mm borosilicate glass tubes as aliquots of 0.3 ml (assay 
volume), and stored at -70°C. 
Preparation of samples for RIA 
For urine samples, 1.5 ml of clear supernatant was used after the crude 
urine was centrifuged at l,500g for 5 min to remove precipitates. For serum 
samples, 200 /xl was used. Each sample was placed in a 100 x13mm borosilicate 
glass tube and then extracted with 3 ml diethylether. 1 ml of the ether extract was 
used for RIA as described previously. 
111.3.3.2. Characteristics of the radioimmunoassay for E2 
Sensitivity 
As in the case of testosterone, twelve replicates of zero standard 
(expressed as % bound of total counts) were pooled and the mean of counts 
bound and the standard deviation (i.e. 41 + / - 1.5%) calculated. A standard 
curve was also constructed by plotting the mean of %bound of 12 replicates of all 
standards as the function of E2 concentration. By the same token, the mean of the 
zero standard plus two S.D. (i.e. 41-44%) was considered as the confidence limit 
of the zero standard, while the mean of the zero standard minus two S.D. 
(i.e. 41-38%) read as concentration (i.e. 2 pg or 7.3 ftnol of E2 per 0.1 ml of 
ethanol) was the minimum detection limit of this standard curve. Moreover, the 
mean and standard deviation of the 12 replicates of charcoal-stripped urine blank 
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was about 41.2 + / - 1.7% which was quite close to the lowest detection limit of 
this standard curve (Fig.7). Again, the levels of sex hormone (E2) in assayed 
biological fluids were orders of magnitude above the minimal detection limits 
[usually in the range of 10 to 20 pg (36.7 to 73.4 fmol)/0.1inl of biological 
fluids], so the lowest detection limit in this situation was not crucial (Chard, 
1990). 
Precision studies 
Within- and between- batch imprecisions 
The within-batch variations of control urines at high (73.4 fmol/tube), 
medium (36.7 fmol/tube), and low (9.2 fmol/tube) levels were noted. Between 
batches, the spiked controls at high, medium, and low levels were always 
processed in the same way as for urine samples. The coefficients of variations are 
summarized in Table III.3.3.2.A and Table III.3.3.2.B. 
Table IIL3.3.2.A. Within-run variation of known amount ofE】 added to charcoal-
stripped urine. 
Volume of 
17P-estradiol charcoal-stripped N CV% 
spiked fmol (pg) urine blank 
73.4(20) — 0.1ml 一 ^ 
36.7 (10) - 0.1ml 20 4.5 
" " ^ 2 . 5 ) 0.1ml I 20 I 21 
Table 111.3,3.2.3, Between-run variation of known amount ofE】 added to charcoal-
stripped urine. 
Volume of 
np-estradiol charcoal-stripped N CV% 
spiked fmol (pg) urine blank 
73.4 (20) 0.1ml 17 10.5 
36.7(10) 一 0.1ml 17 9.7 
一 9 . 2 (2.5) 0.1ml | 17 | 25 
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Fig. 7. The lowest detection limit of the standard curve for estradiol 
A new standard curve of twelve RIA replicates was constructed by plotting the mean counts 
(as % bound) of all standards in these twelve replicates as the function of testosterone 
concentration (pg/0.1ml). The confidence limit (mean+2SD) to the zero standard estimate 
was 44.6%，while the lowest detection limit of this standard curve (mean-2SD) read as 
concentration was about 2 pg/0.1ml (at 37.8% bound). Similarly the lowest detection limit 
using this standard curve by the zero control blank (charcoal-stripped urine) was also 
calculated, which was about the same (38.4% bound), whereas the confidence limit to the 
zero blank estimate (mean+2SD) was 44.4%. The levels of estradiol in assayed biological 
fluids were manipulated in orders of magnitude above the minimal detection limit, therefore, 




The recoveries of spiked control urines at different concentrations were 
calculated from the formula: %Recovery rate = Mean of the 17B-estradiol 
measured + Total 17B-estradiol spiked xlOO. The results were summarized in 
Table III.3.3.2.C. 
Table IIL3,3.2.C. The recoveries of known amount ofE〗 added to charcoal-stripped 
urine, between immunoassays 
17B-estradiol 
17fi-estradiol measured (Mean N Recovery Rate % 
spiked fmol (pg) 土 SEM) pg 
73.44 (20) ~ 18.07 土 0.2 _ 20 • 90.35 
36.72 (10) 9.56 士 0.09 一 20 一 95.6 
9.18(2.5) 2.19 士 0.1 20 87.6 — 
lest of linearity 
A urine pool which showed a high concentrations of urinary unconjugated 
E2 was used for this purpose. Urinary unconjugated E2 was extracted with 3 ml 
of diethylether at various volumes of urine, and the relationship between 
measured E2 and urine volume is shown in Fig.8. 
Comparison with another procedure 
The method was compared with an established commercially-available 
method, Amerlite (Amersham). 
Experimental procedure: 
1. A spiked plasma containing 1101 pmol/L (1101 fmol of E2/ml) was prepared, 
and 5 aliquots were then assayed for E2 by the Amerlite procedure which is 
based on enhanced luminescence competitive immunoassay and used for routine 
purposes at Prince of Wales Hospital. 
2. In parallel, serial dilutions from 300 pg/ml (1101 ftnol/ml) with the charcoal-
stripped plasma blank were made to get concentrations of 150 pg/ml (551 
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Fig, 8, The recovery of unconjugated E2 using various volumes of urine 
after extraction with diethylether. 
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finol/ml), 100 pg/ml (367 fmol/ml), and 50 pg/ml (184 ftnol/ml). 5 samples of 
each dilution were assayed by the "in house" E2 RIA. 
Recovery in the Amerlite procedure was 98.2%, and that for the "in 
house" assay 106% for both 100 pg/ml (367 fmol/ml) and 150 pg/ml (551 
fmol/ml), and 116% for 50 pg/ml (184 fmol/ml). The regression line for 
recovery and expected value is shown in Fig.9 with the equation: E2 observed = 
1.0085 X E2 expected + 6.783 (r=0.99972). The data suggest that this method is 
satisfactory and there is a constant bias which may account for the higher 
recovery using this method. The "in house" RIA was developed due to its desired 
characteristics and is also cheaper. For better precision and recovery, increased 
sample size for assay was usually required (e.g. 200 of serum, 1.5 ml of 
urine). 
I I I . 3.4. For urinary total estradiol 
Similar to urinary total testosterone, most of the urinary E2 is in the form 
of glucuronide or sulfate conjugates which are water soluble. Before extraction 
with organic solvent, therefore, it was necessary to hydrolyze the conjugates. 
Acid hydrolysis was employed. After hydrolysis, the hydrolyzate was diluted 
1:25 with charcoal-stripped urine blank. 0.6 ml of the diluted hydrolyzate was 
then extracted with 3 ml diethylether. One ml of the ether extract was then used 
for RIA as described previously. 
Test of linearity and recovery 
To 1 ml of spiked urine (3 ng/ml), 0.2 ml of 12N HCL was added and 
hydrolysis was carried out in a 100。C water bath for 15 mins. The resulting 
hydrolyzate was diluted with the charcoal-stripped urine blank at the ratio of 
1:25. The final diluted hydrolyzate was then prepared in aliquots of 300/xl, 
600iLil, 900/xl per tube. A l l tubes were extracted with 3 ml of diethylether, 
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and 1 ml of the organic phase was used for RIA, in duplicate. 
There was a linear relationship between the measured E2 concentration 
and the volume of diluted acid hydrolyzate used for extraction (Fig. 10). The 
recovery of E2 was 85%. 
III. 4. Determination of SHBG 
A two-site immunoradiometric assay was used (IRMA Count for SHBG, 
DPC lot no. RKSHI-0173, LLanberis, UK). It is composed of ligand-coated 
tubes and three monoclonal antibodies, of which one is 125i_iabelled, and the 
other two are linked to a ligand. The procedure was as follows: SHBG in the 
sample was first attached to solid phase ligand coated on tube via antigenic site, 
and then captured by the addition of ligand-labelled monoclonal anti-SHBG 
antibodies. The excessive SHBG free-ligand on tube was then separated with the 
second monoclonal antibodies by the ligand-coated tube/antiligand bridge method. 
Finally the bound fraction (SHBG-ligand complex) was reacted with the 125i-
labelled monoclonals via a different epitope on the "captured" ligand, and the 
tube was washed to remove excessive tracer. The washed radio-labelled solid 
phase ( S H B G - l i g a n d - 1 2 5 i complex) was then counted on Packard Cobra Auto-
Gamma counter (Packard Instrument Co., Illinois, USA). Al l standards, controls, 
and samples were run together in the test, and the values of SHBG of samples 
were obtained by interpolation to standard curve. 
111.5. Determination of urinary unconjugated Cortisol 
Urinary unconjugated C o r t i s o l was assayed by DPC RIA kit (DPC coat-a-
count lot no. TK co5-519). The procedure included extraction of urinary steroids 
by dichloromethane, reconstitution of the extract with zero calibrator after 
evaporating off the organic solvent under a stream of nitrogen, and finally RIA as 
per the manufacturer's instructions. The solid phase of the 125i_iabelled antigen-
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antibody complex was counted on a Packard Cobra Auto-Gamma counter. 
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Fig.10. The dose - response curve of measu red u r ina ry 
to ta l E2 vs various volumes of diluted acid hydrolyzate. 
129 
62 
HI. 6. Statistical methods 
HL6.1. Biological Variations 
The components of biological variation were determined following the 
strategies proposed by Fraser (1986) which is based on the principle of nested 
analyses of variance (Fraser, 1989). There are three steps in this strategy: 
(1) Analytical variance could be obtained by data from the duplicate analyses 
using the formula : SDa^ = Sum of (differencef/(2 x no. of pairs). (2) For 
each individual, a single set of data is used to calculate the SD. The variance 
( S D , is made up of analytical and intraindividual variance. SD: = SDa^ + SDi， 
where SDi is intra-individual biological variation. 
(3) Data from all subjects (in singlicate) to calculate total SD ([SD]). The total 
variance [ S D f = SDa' + SdP + SDg^ where SDg is interindividual biological 
variation. Thus, SDg can be calculated. 
A l l biological variations were expressed as SD/Mean x 100% (CV%) to 
avoid the complexity of different units of the parameters. 
in.6.2. Univariate and multivariate correlations 
Pearson's correlation coefficients were used to examine associations 
between variables. Non-parametric statistical analysis (Spearman Rank) were used 
for Lp(a) data due to skewed distribution. 
Stepwise multiple linear regression analysis was performed with 
lipoprotein-lipids levels as the dependent variables and the independent variables 
including potential confounders, removed stepwise (probability for removal 
0.05) to look at the interrelations between hormones and lipoprotein-lipids. Most 
of the experimental subjects were non-smokers (except one ) and non-drinkers or 
drinkers taking small amount of beer or wine. These variables were not 
considered as possible confounders. There were three steps: 
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(a) Step 1. Linear regressions were performed with lipoprotein-lipid levels as the 
dependent variables and anthropometric parameters (BMI, WHR, and Age), 
serum sex hormones, urinary total and unconjugated sex hormones and SHBG as 
independent variables. 
(b) Step 2. Calculated serum unbound sex hormone levels replaced serum total 
sex hormones in the regression, since there was a high degree of multicolinearity 
between them. 
(c) Step 3. Triglyceride was added as one of the independent variables to see the 




Chapter IV. Results 
IV. 1. The characteristics of the experimental subjects and 
their lipoprotein-lipids profiles 
The anthropometric characteristics of 46 apparently healthy Chinese men 
were summarized in Table IV . l .A . The values (Mean 士 S.E.M.) for serum 
albumin, y-glutamyl transferase (yGT) and urinary creatinine were also included 
in this Table. 
Table IV, LA, The anthropometric and biochemical characteristics of the experimental 
male subjects (n=46). 
Parameter Mean (SEM) “ Actual Range 
Age(yrs) — 33(1) 19-53 一 
B M I (kg/m^) 22.6 (0.37) 17.56-30.2 
Waist/Hip 0.85 (0.009) 0.72-1 
Serum albumin (g/L) 一 47.4(0.33) 42.4-52.5 
YGT (U/L) “ 18.1(2.06) 2.5-60 
Urine creatinine (mmol/L) 13.65 (0.35) 8.58-19.34 
As shown in Table IV . l .B . their lipoprotein-lipids expressed as the mean 
(士S.E.M.) values were: 4.79土0.15 mmol/L for cholesterol; 1.3士0.11 mmol/L 
for triglyceride; 2.9 ±0.14 mmol/L for LDL-C; 1.29土0.04 mmol/L for HDL-C; 
0.38土0.031 mmol/L for HDL2-C; and 0.92±0.023 mmol/L for HDL3-C. 
Expressed as mass concentrations, the values (mean 士 S.E.M.) for apoA-I 
and apoB were 1.45士0.029 and 1.36土0.029 g/L, respectively. The actual range 
for L p ⑷ is 55-868 mg/L with a mean value of 168.18 mg/L and the distribution 
of Lp(a) is highly skewed in this population. 
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Table IV.l.B, The lipoprotein-lipids profiles in 46 healthy Hong Kong Chinese men 
aged 19-53 yr. 
“Parameter Mean (SEM) Actual Range 
Cholesterol (mmol/L) 4.79(0.15) 2.8-7.0 
Triglyceride (mmol/L) 1.3(0.11) 0.49-3.40 
LDL-C (mmol/L) 2.9(0.14) 1.23-4.95 
HDL-C (mmol/L) 1.29 (0.04) 0.84-2.02 
HDL2-C (mmol/L) 0.38 (0.031) “ 0 . 1 3 - 0 . 9 6 
HDL3-C (mmol/L) 0.92 (0.023) 0 . 6 3 - 1 . 2 5 
Apo A-I (g/L) 1.45 (0.029) 謹--1.84 
Apo B (g/L) 1.36 (0.029) 0.98-1.79 
Lp (a) [mg/L] 168.18 * 一 55-868 
本 Population showed a skewed distribution. 
IV. 2. Levels of sex hormones in serum and urine, and 
urinary free Cortisol 
As shown in Table IV.2, the mean value for the excretion of urinary un-
conjugated testosterone was 1.39 nmol/d which is a very small proportion (about 
1.2%) of urinary total testosterone (98 nmol/d). The mean value of urinary un-
conjugated estradiol was 142.8 pmol/d ( < 1% of the total) and that of urinary 
total estradiol was 16.85 nmol/d. The value (mean±S.E.M.) for serum 
testosterone was 21 士 1.14 nmol/L, whereas that for serum estradiol was 
139 土4.65 pmol/L. 
Since it is difficult to assay serum unbound sex steroids directly, their 
concentrations were calculated by the formula proposed by SodergM et al. 
(1982)，using the association constants for steroid binding to SHBG and albumin. 
The formulae are shown in Table IV.2.A and Table IV.2.B. The calculated 




6.78 pmol/L respectively. When expressed in terms of percent of the total, the 
range for testosterone was 2.7-3.6 % and the range for E〗was 2.97-3.02 %. It 
is noteworthy that the unbound fractions of testosterone and E2 are quite similar, 
？ in terms of percentage, and with a very narrow range among the individuals. 
With a range of 8.75 nmol/L to 46.75 nmol/L, the mean (土SEM) of 
values for SHBG concentration was 32.7土 1.37 nmol/L in this group of Chinese 
men. 
The urinary free Cortisol in this population was in the range of 42 nmol/d 
I 
i to 262 nmol/d with a value (mean 土SEM) of 143 ±8.15 nmol/d. 
'i i 1 
1 
Table IV. 2, The sex hormones at serum and urinary levels and urinary free Cortisol 
in 46 healthy Hong Kong Chinese men. 
I. 
\ Parameter Mean (SEM) Actual Range 
t i 
t U-free testosterone (nmol/d) 1.39(0.15) 0.59-6.49 
U-total testosterone (nmol/d) 98 (7.8) 50 -278 
U-free-E2 (pmol/d) 142.8(9.9) 45.3-328.8 
f U-total E2 (nmol/d) 16.85 (0.81) 6.65-31.82 
U-F-testo/U-total testo x 100 % 1.6 % ~ 0.55-7.6% 
: U-F-E2 / U-total E2 X 100% 09% 0.27-1.72% 
i S-total testosterone (nmol/L) 21 (1.14) 12.6-57.5 j 
I S-free testosterone, calculated 0.66 (0.03) 0.40--1.56 
I (nmol/L) 
I S-total E2 (pmol/L) 139.2 (4.65) 74.4-224.5 
S-free E2，calculated (pmol/L) • 4.15(0.14) 2.21-6.78 
！ SHBG (nmol/L) “ 3 2 . 2 ( 1 . 3 7 ) 8.75-55.5 ( 、 






Table IV.2.A. Formula for the indirect calculation of unbound (free) 
testosterone levels in plasma • 
T = ( K t x T f x S ) + ( l + K t x T f + K E x E f + K D x D f + KAa x Aaf 
+ K A e X A e f ) + K A ^ x A x T f + T f 
T = Total Testsosterone (mol/L) 
‘ K t = Association constant for binding of Testosterone to SHBG 
= 5.97 X e8 M - i 
I T f = Free Testosterone (mol/L) 
“ S = Sex Hormone Binding Globulin (mol/L) 
K E = Association constant for binding of Estradiol to SHBG 
= 3 . 1 4 xe8 M - i 
E f = Free Estradiol 
= 4 . 8 0 X e-12 mol/L 
K D = Association Constant for binding of 5 alpha-Dihydrotestosterone to SHBG 
= 1 0 . 7 X e8 M - i 
D f = Free Dihydrotestosterone 
！ = 67.1-351.0 xe-11 mol/L 
KAa = Association Constant for binding of 5 alpha-androstane-3 alpha, 17B-diol 
to SHBG 
=6 .45 X e8 M - i 
I Aaf = Free 5 alpha-androstane-3 alpha, 17B-diol 
=33.5-80.7 X e-11 mol/L 
KAe = Association Constant for binding of 5 alpha-androstene-3 alpha, 17J5-diol 
to SHBG 
= 4 . 2 4 X e8 MP 
Aef = Free 5 alpha-androstene-3 alpha, 176-diol 
=200-585 X e-11 mol/L 
K A i = Number of binding sites for Testosterone on each molecule of Albumin 
multiplied by the Association Constant for the binding of Testosterone to 
Albumin 
= 4 . 0 6 X e4 M - i 
A = Albumin Concentration (mol/L)+ 
+ Molecular weight for serum albumin is 69,000 
• Sdderg红d,R.; Backstrom, T.; Shanbhag, V.; and Carstensen, H. (1982) 
Calculation of free and bound fractions of testosterone and estradiol-17B to 
human plasma proteins at body temperature. J. Steroid Biochem. 16:801-810 
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Table IV.l.B. Formula for the indirect calculation of unbound (free) IJfi-
estradiol levels in plasma* 
E2 = ( K E X E f X S ) + ( 1 + K t X T f + KE X Ef + K D X Df + KAa x Aaf 




E2 = Total m-estradiol (mol/L) 
K t = Association constant for binding of Testosterone to SHBG 
= 5 . 9 7 xe8 M- i 
T f = Free Testosterone (mol/L) 
S = Sex Hormone Binding Globulin (mol/L) 
K E = Association constant for binding of Estradiol to SHBG 
= 3 . 1 4 xe8 M- i 
Ef = Free Estradiol (mol/L) 
K D = Association Constant for binding of 5 alpha-Dihydrotestosterone to SHBG 
= 1 0 . 7 X M- i 
I 
Df = Free Dihydrotestosterone 
=67.1-351.0 xe-11 mol/L 
KAa = Association Constant for binding of 5 alpha-androstane-3 alpha, 1713-diol 
to SHBG 
二 6.45 X e8 M - i 
Aaf = Free 5 alpha-androstane-3 alpha, 17B-diol 
=33.5--80.7 x e - l l mol/L 
KAe = Association Constant for binding of 5 alpha-androstene-3 alpha, 17B-diol 
to SHBG 
= 4 . 2 4 x e 8 M - i 
Aef = Free 5 alpha-androstene-3 alpha, 17B-diol 
、 =200-585 x e - n mol/L 
KA2 = Number of binding sites for 17B-estradiol on each molecule of Albumin 
multiplied by the Association Constant for the binding of 17B-estradiol 
to Albumin 
= 4 . 2 1 X e4 M- i 
A = Albumin Concentration (mol/L)+ 
躲 
+ Molecular weight for serum albumin is 69,000 
* S6dergard,R.; Backstrom, T.; Shanbhag, V.; and Carstensen, H. (1982) 
Calculation of free and bound fractions of testosterone and estradiol-17B to 







IV. 3. Biological variations 
Table IV,3. is a summary of the biological variations of serum 
lipoprotein-lipids, serum and urinary sex hormones and Cortisol in 46 healthy 
Chinese men. Table IV.3.A and Table IV.3.B show the correlation of serum 
lipoprotein-lipids, sex hormones, as well as urinary sex hormones between 
samples taken approximately three weeks apart. 
Table TV3, The biological variations* of serum lipoprotein-lipids, serum sex 
hormones and urinary sex hormones and Cortisol in 46 healthy Hong Kong Chinese 
men aged 19-53 years 
Variables No. of CVa (%) CVi (%) CVg (%) Index of 
subjects individuality 
I I I I I (CVi/CVg) 
Lipoprotein-
lipids 
Triglyceride 46 1.7 23.9 34.9 0.7 
Cholesterol 46 2.3 6.3 20.8 03 
Lp(a) 46 — 5.5 — 14.3 “ 102 
HDL 46 3.8 5.7 ^ 03 
HDL2 46 11.4 — 14.8 53 03 
HDL3 46 4.1 — 6.1 15.1 OA 
apoA-I 46 1.8 4 U J 
apoB 46 1.2 4.7 13.4 0.4 
Hormones 
S-E2 46 6.6 23.4 8.7 _2J 
S-Tcstosterone 46 4.1 — 9.2 — 35.4 03 
U-totalE2 46 — 4.9 ^ 16.85 1.8 
U-free E2 46 T T 38.5 ^ y 
U-total Teste 46 — 7.2 — 25 47.3 OJ 
U-free Teste 46 51J 6]A 
U-free Cortisol I 46 7.8 19.7 27.7 0.7 
CVa=analytical variation as coefficient of variation 
CVi=intra-individual variation as coefficient of variation 
CVg=inter-individual variation as coefficient of variation 
* The components of variation were calculated after Fraser (1986), with 
untransformed data. 
‘ 
f • • 
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Table IV,3A, Correlations of serum lipoprotein-lipids between short-term (3-week) 
variations in 46 healthy Hong Kong Chinese men 
Parameters r p 
l^glyceride — 0.75 < 0.0001 — 
Cholesterol 0.89 < 0.0001 
apoA-I 0.88 < 0.0001 
apoB 0.94 < 0.0001 
； HDL-total 0.90 < 0.0001 
HDL2 0.88 < 0.0001 
HDL3 0.80 < 0.0001 
Lp(a) 0.98 < 0.0001 
Table IV.3.B. Correlations of serum and urinary sex hormones and urinary 
unconjugated Cortisol between short-term (3-week) variations in 46 healthy Hong Kong 
Chinese men 
parameters r p 
S-testosterone 0.9 < 0.0001 
S-17fi estradiol 0.15 NS 
U-total E2 "a36 0.015 
U-unconjugated E2 0.36 0.015 
U-total testosterone <0.0001 
U-unconj. testosterone 0.48 0.001 
U-unconj. Cortisol 0.6 <0.0001 
The subjects were asked not to change their life style to try to minimize pre-
analytical sources of variation. Al l blood samples were collected sitting between 
8:30 am to 10:00 am. Among variables serum testosterone showed good 
， agreement between short-term repeated samples (r=0.9), while serum E2 did not 
show any significant correlation (Table IV.3.B.) implying greater biological 
variability. The greater correlation between duplicates for urinary estradiol 
(r=0.36, p=0.015) than for serum estradiol (r=0.15, NS) suggests that the use 
of urinary estradiol as an index of estradiol production could be more useful. 
However the intraindividual variability of 17 P-E2 in serum is greater than that of 
serum testosterone (CVi = 23.4, 9.2 respectively) (Table IV.3). and therefore, 






The index of individuality was calculated as CVi/CVg (Fraser, 1986). 
Lp(a) had the least index of individuality (0.14)，while serum E2，urinary total 
E2 and urinary unconjugated E2 had the largest indices of individuality (2.7, 1.8, 
1.5, respectively) among all assayed parameters. 
For lipoprotein-lipids, all show good agreement between these two 
occasions (Table rV.3.A). Lp(a) and apoB appear to be the most stable in this 
population (r=0.98, 0.94 respectively), whereas triglyceride shows the greatest 
short-term variation (r=0.75). Cholesterol, HDL-C, and HDL subfractions-
HDL3-C and HDL2-C, as well as apoA-I are in between with correlation 
coefficients of 0.89, 0.9，0.88，0.80, 0.88 respectively. 
It is noteworthy that the HDL3-C has less intra- and inter- individual 
variations than those of HDL2-C. 
IV. 4. Univariate correlation 
The scatter graphs for univariate correlation are compiled in Appendix i i . 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































IV.4.1. IfUer-relatiomhip among serum and urinary sex hormones 
The urinary non-conjugated E2 was significantly correlated with both 
urinary total E2 (r=0.353, p=0.016) and serum total E2 (r=0.325, p=0.027). 
Neither urinary total E2 nor urinary total testosterone was correlated with serum 
total estradiol and testosterone. Urinary non-conjugated E2 and testosterone were 
significantly correlated with serum total estradiol and testosterone, respectively, 
with r=0.325, p=0.0274 and r=0.596, p<0.0001 ( Appendix i i . f - i i .g) . 
The serum E2 was significantly correlated with the serum testosterone 
with r=0.57530, p<0.0001. (Appendix ii.g). However, urinary total 
testosterone was not correlated with urinary non-conjugated testosterone. 
IV.4.2. Urinary free Cortisol and sex hormones and serum 
lipoprotein-lipids 
Interestingly the urinary free Cortisol is positively correlated with both 
urinary total and unconjugated testosterone (r=0.317, p=0.032; r=0.397, 
p=0.0062, respectively) (Appendix ii.g) but neither correlated with serum 
testosterone and estradiol nor correlated with urinary total and unconjugated 
estradiol. However, urinary free Cortisol concentrations showed no significant 
associations with any lipoprotein variable. I f this is not due to chance, an 
explanation is not immediately apparent. 
IV. 4.3. Correlation between urinary sex hormones and serum 
lipoprotein-lipids 
As shown in Table IV.4 and Appendix i i .f, the urinary unconjugated E2 
excretion is directly but weakly associated with the serum levels of Lp(a) 
(r=0.3662, p=0.0123) (for untransformed data only) and HDL3-C (r=0.3073, 
p=0.038), and this association is even stronger in terms of percent urinary 
unconjugated E2 excretion {with r=0.387, p=0.008 (for untransformed data 
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and total serum testosterone show a weak direct relationship with HDL, HDL2, 
apoA-I, and SHBG and a stronger inverse relationship with triglyceride. 
(Appendix ii.o.). Unbound and total serum E2 are inversely and weakly 
correlated with cholesterol, triglyceride, and LDL and directly with HDL2 again 
weakly, but not with HDL and apoA-I. (Appendix ii.m.). 
IV. 4.6. Correlations between anthropometric variables, sex 
hormones and lipoprotein-lipids 
Age is positively correlated with cholesterol (r=0.339, p=0.021) and 
LDL-C (r=0.352, p=0.0166) (Appendix u.c.) and inversely with the calculated 
serum unbound E2 (r=-0.340, p=0.0209), serum total testosterone (r=-0.309, 
p=0.0364), and urinary un-conjugated testosterone (r=-0.337, p=0.0218). (See 
Appendix ii.a.). No correlation is found with the urinary E2 level. Age is 
directly associated with BMI (r=0.293, p=0.0478), WHR (r=0.508, p=0.0003) 
(Appendix ii.d.), and yGT (r=0.41128, p=0.0045) (Appendix u.b.). 
BMI is positively correlated with cholesterol (r=0.397, p=0.0063), 
triglyceride (r=0.589, p<0.0001)，LDL-C (r=0.372, p=0.0109) (Appendix 
ii.c.), WHR (r=0.564, p<0.0001), yGT (r=0.442, p=0.0021), and age 
(Appendix ii.d). An inverse correlation is found between BMI and the calculated 
serum unbound and the serum total testosterone (r=-0.42454, p=0.0033 and r = -
0.407, p=0.0050, respectively) (Appendix u.d.), HDL (r=-0.402, p=0.0056), 
HDL2 (r=-0.543, p<0.0001), HDL2/HDL3 (r=-0.570, p < 0.0001) 
(Appendix u.c.) and SHBG (r=-0.32947, p=0.0254) (Appendix u.d). 
WHR is directly associated with cholesterol (r=0.336, p=0.0226), 
triglyceride (r=0.325, p=0.0277), LDL-C (r=0.343, p=0.0195) (Appendix 
i i ,r .), yGT (r=0.420, p=0.0037) and age (r=0.50787, p=0.0003) (Appendix 
ii.d.), and inversely with HDL2-C (r=-0.356, p=0.015) and HDL2/HDL3 
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(r=-0.370, p=0.012) (Appendix ii.r.). No association was found with any 
serum or urinary sex hormone variable. 
yGT, interestingly, is positively correlated with all anthropometric 
variables (BMI, WHR, and Age) (r=0.442，p=0.0021; r=0.420, p=0.0037; 
r=0.411, p=0.0045, respectively) (Appendix ii.b. & Appendix ii.d.) and with 
all atherogenic lipoprotein-lipids (Cholesterol, Triglyceride, LDL-C, and ApoB) 
(r=0.448, p=0.0018; r=0.474, p=0.0009; r=0.441, p=0.0022; r=0.291, 
p=0.0501, respectively) (Appendix ii.h.), but inversely with the serum 
testosterone (both the unbound and the total) (r=-0.391, p=0.0072 and 
r=-0.364, p=0.0128, respectively) and the anti-atherogenic lipoprotein-lipids 
HDL and HDL〗 and HDL2/HDL3, with r=-0.310, p=0.0361; r=-0.449, 
p=0.0018; and r=-0.461, p=0.0012, respectively (Appendix u.h). 
SHBG is positively associated with serum testosterone (r=0.516, 
p=0.0002) (Appendix ii.o.), HDL-C (r=0.373, p=0.0107), and HDL2-C 
(r=0.398, p=0.0062) and inversely associated with triglyceride (r=-0.436, 
p=0.0025) (Appendix u.n.) and BMI (r=-0.330, p=0.0254) (Appendix ii.d.). 
IV. 4.7. Correlation of the ratio ofHDL】 and HDL 3 and other 
variables 
HDL2/HDL3 is directly correlated with the serum testosterone (both 
unbound and total) (r=0.504, p=0.0004; r=0.466, p=0.0011, respectively) 
(Appendix ii.o.), and SHBG (r=0.379, p=0.0095) (Appendix ii.n.). 
The ratio is inversely correlated with cholesterol (r=-0.325, p=0.0275) 
(Appendix u.e,), LDL-C (r二-0.416, p=0.004) (Appendix ii.k.), triglyceride 
(r=-0.489, p=0.0006) (Appendix, ii.p.). It is also associated with BMI 
(r=-0.570, p < 0.0001) (Appendix u.c.), WHR (r=-0.370, p=0.012) 
(Appendix i i.r.), and yGT (r=-0.461, p=0.0012) (Appendix ii.h.). The 
correlations with total HDL (r=0.676, p < 0.0001) (Appendix iU.)，apoA-I 
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(r=0.427, p=0.0031) would be expected. 
IV. 5. Multiple linear stepwise regression 
Table IV.5, Stepwise multiple linear regression of lipoprotein-lipids* 
(dependent variable) on BMI, W/H Ratio, and Age (independent variables) in 
46 healthy Chinese men aged 19-53 years, 
t and p values are indicated, 
Depende 
nt ApoAI 








BMI {t) +2.870 + 4.829 + 2.660 -2.913 -4.285 -4.602 
{p) 0.0063 < 0.0001 0.0109 0.0056 <0.0001 <0.0001 
WHR 
I • • • < » _ _ • 
^ 
» All data were not transformed 
The initial result from multiple linear regression of lipoprotein-lipids 
(dependent variable) on the anthropometric variables BMI, WHR, and age (Table 
IV.5) indicates that BMI is directly and significantly associated with cholesterol 
(r=+2.8698, p=0.0063), triglyceride (玄=+4.8289，p<0.0001), and less 
strongly with LDL-C with p=0.0109. It is also inversely associated with HDL-C 
(/=-2.9127, /?=0.0056), HDL2-C (£=-4.2853, /KO.OOOl), and the ratio of 
HDL2-C and HDL3-C with 玄=-4.602, 0.0001. No association is found with 
apoA-I, apoB, Lp(a) and HDL3-C. Neither age nor WHR in this population has 
significant correlation with lipoprotein-lipids in the model. 
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After adjustment for BMI, WHR, Age, SHBG, and sex hormones (serum 
and urinary levels), as shown in the Table IV.S.A, the levels of HDL3, apoB, 
and untransformed Lp(a) are directly ( r=+2.8, =0.0076; ^=+2.32, p=0.025; 
^=+2 .6 , /?=0.0123, respectively) whereas the level of triglyceride (^=-2.06, 
=0.046) inversely correlated with the urinary excretion of unconjugated 
estradiol. The urinary total E2 excretion is inversely correlated with cholesterol 
(r=-2.60, p=0.0126), LDL-C (r=-2.53, /?=0.0153), HDL3 (r=-2.05, 
p=0.0468), and apoB (r=-3.06, p=0.0038). B M I remained strongly positively 
correlated with cholesterol ( /=+3.23, p=0.0024), triglyceride (玄=+4.46， 
p<0.0001), LDL-C (r=+2.98，p=0.0046), and inversely with HDL2 (《=-3.10， 
；,=0.0034). 
HDL-C is directly associated with serum total testosterone ( r=+3.16, 
/?=0.0028) and serum •free' testosterone (r=+3.44,p=0.0013). 
Triglyceride is not significantly associated with testosterone when 
adjusted for SHBG and anthropometric confounders including BMI, but reaches 
borderline significance with the urinary unconjugated E2 excretion (,=-2.06， 
及=0.046). However, it is strongly, persistently, and directly associated with BMI 
(t= +4.455, p <0.0001)and inversely associated with SHBG (t=-2.6, / i=0.014). 
Furthermore, since the metabolism of total HDL and its subfractions 
associates closely with triglyceride concentrations (Patsch et al., 1983，1987; 
Silverman et al” 1993), triglyceride was also included in the model for the 
relationship of HDL-C and sex hormones. As shown in Table IV.S.B, after 
triglyceride concentration was included in the model, the relationship between 
urinary E2 (both total and non-conjugated) and HDL3-C did not change, as did 
not the associations between serum testosterone (both total and unbound) 
with HDL2-C (^=+2.60, /?=0.0128 and 玄=+2.90，p=0.0052, respectively). 
However, the association of BMI with HDL seen univariately was abolished after 
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Table IV.SA, Stepwise multiple linear regression of lipoprotein-lipids* 
(dependent variable) on BMI, W/H Ratio, Age, SHBG, and serum and 
urinary Sex Hormones (independent variables) in 46 healthy Hong Kong 
Chinese men aged 19-53 years, 
t and p values are indicated. 
Depttident 
variable 
+ Choi Trig LDL HDL HDL2 HDU Apo Apo Lp ⑷备 
In-depoidait A-I B 
variable 
± 
FU-E2 {0 -2.06 + 2.8 + 2.32 +2.6 
^ 0.046 ： - - 0.0076 - 0.025 0.0123 
TU-E2 (0 -2.60 -2.53 -2.05 -3.06 
ip) 0.0126 - 0.0153 ：： - 0.0468 - 0.0038 -
S-F-E2 (/) -2.04 
_ • - - - - - -
姐 0.0477 
S-Test it) +3.16 +2.60 
^ - - 0.0028 0.0128 ： ： ： -
S-F-Testo (t) +3.44 +2.90 
{p) - - 0.0013 0.0052 - - - -
BMI it) +3.23 + 4.455 +2.98 -3.10 
(p) 0.0024 < 0.0001 0.0046 - 0.0034 - ： ： ： 
SHBG (/) -2.6 +2.37 
to) I - I 0.014 - I - I - I - 0.02 - I -
* All data were not transformed 
§ When transformed Lp(a) concentrations were added in the place of raw skewed data the 
positive association with urinary nuconjugated E2 was no longer significant. 
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Table fV.S.B. Stepwise multiple linear regression of lipoprotein-lipids* (dependent 
variable) on BMI, W/H Ratio, Age, SHBG, Triglyceride and serum and urinary 
Sex Hormones (independent variables) in 46 healthy Hong Kong Chinese men aged 
19-53 years, t and p values are indicated 
Dependent 
variable 






FU-E2 (t) +2.8 
• • 垂 
(p) 0.0076 
TU-E2 (0 -2.05 
(p) - 0.0468 
S-F-E2 
• • • • 
S-Test (t) +2.60 
(p) - 0.0128 - -
S-F-Testo 
(i) +2.12 +2.94 
• • 
(p) 0.0401 0.0052 
BMI it) ~ 
- 0.0034 - -
(P) 
TU-testo 
• • • _ 
"lYii“it) ^JM 
• _ • 
(p) 0.0006 
SHBG (t) +2.37 
• • _ 
(p) 0.02 
• All were un-transformed raw data 
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Chapter V. Discussion 
V. 1. Experimental subjects and their lipoprotein-lipids 
profiles 
As summarized in Table I V . l . B , the mean (±S.E.M.) values of 
lipoprotein-lipids in 46 apparently healthy Chinese men were all in the range 
typical of normal western men (Mart ini et al” 1984). HDL3-C level in men was 
higher than that of HDL2-C. That is in line with the typical pattern documented 
in the literature (Anderson et al； 1978; Martini et aL, 1984; Atger et al” 1990). 
I t is noteworthy that there is no difference in values for these lipoprotein-lipids 
profiles between the Caucasian and the Hong Kong Chinese. The total variation 
expressed as CV% in HDL2-C is 56.2 which is much higher than that for 
HDL3-C (16.8 %), i.e. HDL2-C is more variable between individuals than 
HDL3-C. The values (Mean土S.E.M.) for apoA-I and apoB were 1.45±0.029 and 
1.36+0.029 g/L, respectively, and are higher than those reported by Masarei et 
al. (1986) (1.31 士0.03 and 1.11 土0.05 g/L). Different specificity of the 
antiserum and the standardization of the method might have accounted for the 
slight difference in values. The range of apoA-I concentration of our present 
study (1.06-1.84 g/L) appears to be close to that reported by Chambless et al. 
(1992) (0.96-1.72 g/L). However, it must be pointed out that the latter was 
obtained by combining values of 17 males and 23 females. Lp(a) concentrations 
(55-868 mg/L) are in the same order as those (20-750 mg/L) reported by 
Sandholzeri et al. (1992) among Singapore Chinese. Although there is 
considerable variation between individuals in this population, these two 
populations of Chinese individuals appear to have comparable levels. Lp(a) 
assays are not well standardized and therefore comparison of populations is 
difficult. As shown in Table IV.3, HDL3-C has less intra- and inter- individual 
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variations than those of HDL2-C. It has been documented that variations in 
HDL-C concentration both between and within subjects are mostly due to 
changes in subfraction HDL2-C, and the level of HDL3-C in men is rather 
constant (Anderson, 1978, Wood & Haskell, 1979; Puchois et al” 1987). The 
value of HDL2-C was obtained by subtraction of HDL3-C from HDL-C, 
therefore greater analytical variation might be expected. From the values of CVi 
and CVa, obviously, improvement in determination of HDL-C and its 
subfractions should be sought, since CVa > 1/2 CVi (Fraser, 1986). 
Lp(a) has the least index of individuality (0.14). The very low index of 
individuality of Lp(a) is a reflection of the small change between short-term 
repeated samples. When the index of individuality is low, particularly less than 
0.6, the variable has a relatively wide reference range with respect to the range of 
intraindividual variation, and the conventional reference values are of little help 
in making decisions about the probability of a result representing a 'normal' 
value for that individual (Fraser, 1986). The index of individuality of the serum 
lipoprotein-lipids is generally low. However it has become accepted practice to 
specify upper or lower 'desirable' values based upon risk data from population 
studies. 
The correlation coefficient between HDL and apoA-I (r=0.859) is in 
agreement with that of Vaisanen et a/.(1992) (r=0.803)，and of Levinson & 
Wagner (1992) (r二0.874). Also apoB, the protein moiety of LDL-C is strongly 
correlated with LDL-C and the correlation coefficient of r=0.856 is in agreement 
with that of Vaisanen et al, (r=0.856). ApoB is also strongly correlated with 
total cholesterol with a corrlation coefficient in agreement with that of Levinson 
& Wagner (r=0.918 in this experiment, and r=0.866 for the latter). As 
expected, HDL-C and HDL2-C are correlated inversely with triglyceride. Since 
HDL-C is strongly positively associated with HDL2-C, and HDL2 is involved in 
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the clearance of triglyceride as documented (Anderson, 1978; Fielding and 
Fielding, 1981; Patsch et al” 1983, 1987，1992; Martini et al； 1984; Silverman 
et al” 1993), the metabolism of HDL-C is associated closely with triglyceride. 
HDL3 is directly correlated with LDL-C (r=0.450，p=0.0017) and apoB 
(r=0.51927, p=0.0002) and the association with the latter is even stronger than 
the former. This may imply that there is some metabolic connection between 
HDL3 and apoB, since the cholesterol-lowering drug nicotinic acid also decreases 
HDL3 levels (B lum et al” 1977; Shepherd et al., 1979). 
The untransformed Lp(a) does not correlate with any lipoprotein-lipids 
except, weakly but significantly with LDL-C (r=0.3, p=0.028). A possible 
explanation is that the present experimental protocol for estimating LDL-C 
actually includes Lp(a)-cholesterol in the value for LDL-C as Lp(a) is 
precipitated by MgCl2-dextran sulfate during the procedure for measurement of 
HDL-C，the calculated value for LDL-C actually represents non-HDL-cholesterol 
which contains both LDL and Lp(a). After subtracting the Lp(a) value from that 
of the calculated LDL-C, the true LDL-C value and Lp(a) are not correlated. 
Similar results have also been reported in a study when heparin-manganese was 
used as a precipitating agent for separation of HDL-C and LDL-C, and the 
Friedewald formula was used for calculation (Dahlen et al” 1986). 
V. 2. Levels of sex hormones in serum and urine 
The values of sex steroids in 46 healthy Chinese men are compared with 
others cited in literature as shown in Table V.2. It seems that the present results 
are comparable. In terms of concentrations both unbound fractions are highly 
correlated with serum total levels (r > 0.99), possibly, at least partly, due to the 
fact that total testosterone and total estradiol are factors in calculation of both 
variables, and the correlation may be partly spurious. It also suggests they are 
giving similar information. 
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Table V.2. Values of sex steroids in 46 healthy Hong Kong Chinese men (aged 19-53 
years) compared to others cited in literature 
Variable Chinese (ii=46) Others * 
Ref. 
U-f-Testo 1.39±0.15 1.43 (median) 1 
(meandbSEM) 0.65—3.16 1 
(range) nmol/d 0.59—6.49 0.18—7.08 la 
1.34 (mean) lb 
U-T-Testo 
(mean±S£M) 98±7.8 121.5—399.3 2 
(range) nmol/d 50—278 173.5—468.5 (20-50yr) 3 
138.8—208.2 (> 50yr) 3 
204.9 4 
291.7 J 
U-f-E2 (meanitSD) 142.8±67 200±130 
(range) pmol/d 45.3—328.8 6 
U-T-E2 (meaniSD) 16.85±5.5 
(range) nmoi/d 6.65—31.82 I 
S-T-Testo (meaniSD) 21±7.7 25.2±8.7 (n=243,36-61yr) 2 
13.7 (n=98, 52-74yr)(Japanese) 7 
19.85±4.68 3 
(range) nmol/L 12.6—57.5 10.42—29.5 (n=14,20-28yr) 8 
S-T-E2 (mean±SD) 139.2±31.5 




(mean ± SD) 4.15±0.95 
(range) pmol/L 2.216.78 
% of total (meaniSD) (2.98±9.7e-5) % 




(range) nmol/L 0.40—1.56 
% of total (meanikSD) (3.2±0.17) % 
(range) % (2.7—3.6) % (0.9-5.5) % * 
• by the method of Sodergard et al. (1982) J. Steroid Biochem. 16:801-810 
来references listed under appendix iii. 
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The present results are within the ranges reported in the literature as reviewed 
by Sodergad (1982). However, the urinary unconjugated testosterone (with the 
value of 0.6-7.6% of the total) and estradiol (with the value of 0.27-1.7% of the 
total) have very wide ranges of variation between the individuals. This probably 
indicates that there are great variations between individuals in terms of 
production and metabolic clearance rates. 
As shown in Table IV.2, the excretion of urinary un-conjugated sex 
hormones is of a very small proportion (about 1-2%) of the urinary total sex 
hormones. This indicates that most of the sex hormones are excreted as 
conjugated metabolites rather than in an unmetabolized form. 
SHBG, with a range of 8.75 nmol/L to 46.75 nmol/L and a coefficient of 
variation about 29% among the population, is significantly affected by BMI with 
a Pearson's correlation coefficient of -0.33 (p=0.0254)，but not by age and 
WHR. The mean (士SEM) of values for SHBG concentration is 32.7土 1.37 nmol/L 
in this group of Chinese men, and 20.02±2.9 nmol/L in a group of Caucasian 
men reported by Peiris et al. (1993). BMI, WHR and age are said to be factors 
affecting SHBG concentration. The values for BMI, and WHR were similar in 
the two groups, although the age in Chinese men tended to be older (SHBG levels 
increase with age). We can not be sure that the assays were similarly 
calibrated, but it is possible Chinese men have higher values for SHBG. 
Nevertheless, both groups of healthy male subjects have lower values than 
healthy women (the range of mean values is 39.7-45 nmol/L in females aged 20-
69 years) (Preziosi et al” 1993). 
As shown in Table IV.3.B serum testosterone showed good agreement 
between short-term repeated samples (r=0.9). This finding is in agreement with 
the view that plasma testosterone level in men is fairly constant (Lipsett et al” 
1968). It also lends support to the suggestion that measurement of plasma 
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testosterone in men by using only a single morning blood sample is satisfactory 
and convenient for epidemiological purposes (Dai et al” 1981). However the 
greater intraindividual variability of 17 p-E2 (Table IV.3) in serum suggests that 
the repeated measurement of E2 in men would seem to be preferred. Serum E2， 
urinary total and unconjugated E2 have the largest indices of individuality (2.7， 
1.8，1.5, respectively) among all assayed parameters. When the index of 
individuality is high, particularly greater than 1.4，the population reference range 
is of more use (Fraser, 1986). 
The results showed that urinary non-conjugated E2 was significantly 
correlated with both urinary total E2 and serum total E2. Since only a very small 
amount of E2 is derived from extraglandular transformation of androstenedione 
and most E2 in men is directly secreted or transformed from the secreted 
testostosterone by aromatization (Bardin, 1986), the measurement of the urinary 
E2 both in conjugated and/or non-conjugated forms would be expected to reflect 
the production and/or secretion rate of £2- The results also showed that urinary 
non-conjugated E2 and testosterone were significantly correlated with serum total 
testosterone and estradiol, but that both the urinary total E2 and testosterone were 
not correlated with serum total testosterone and estradiol. Since most of the 
serum testosterone in males is secreted by the testes (Lipsett et al” 1968), the 
correlation between urinary non-conjugated testosterone and serum testosterone 
concentration implies that its secretion rate is likely to be a determinant of 
urinary non-conjugated testosterone excretion. By the same token, the secretion 
rate is probably a determinant of urinary non-conjugated E2 excretion, although 
most serum E2 derives from the transformation of serum testosterone rather than 
from the secretion. The urinary total testosterone also reflects androgen from 
other sources as well and might be expected to be less strongly correlated with 
serum testosterone levels. 
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As expected, the serum E2 is very significantly correlated with the serum 
testosterone, because the serum testosterone is the source of most serum E2 in 
normal men (Bardin, 1986). But also, both are highly bound to SHBG which 
would determine their serum concentrations. 
V.3. IVfi-Estradiol, atherogenic lipoprotein-lpids and 
HDU 
Over all, the data presented here suggest that the urinary excretion of 
unconjugated E2 is directly associated with serum apoB, Lp(a) (for 
untransformed data only), and HDL3 concentrations; while the urinary excretion 
of total E2 is inversely correlated with cholesterol, LDL-C, apoB, and possibly 
HDL3. Calculated serum unbound E2 concentration and urinary unconjugated E2 
excretion had inverse and direct associations respectively with apoB levels after 
multiple linear regression which may be due to chance, as they were not 
significantly associated univariately. A similar explanation is proposed for the 
inverse correlation between HDL3-C concentration and total urinary E2 
excretion. The most suggestive feature of this study is the finding of an inverse 
correlation between the urinary 17P-estradiol excretion rate and cholesterol, 
LDL-C and apoB which are strong risk factors for atherosclerosis (Levinson and 
Wagner, 1992). 
Lp(a) concentration in men is rather stable throughtout life (Lawn, 1992). 
Apo(a) genes determine the total plasma Lp(a) concentrations, but, the apo(a) 
gene only accounts for approximately 40% of the variation in Lp(a) levels (Scanu 
& Fless, 1990)，though a more recent paper shows that the apo(a) gene is 
estimated to be responsible for 91% of the variance of plasma Lp(a) concentration 
(Boerwinkle et al” 1992). It has also been suggested that the LDL receptor gene 
may have an effect on plasma Lp(a) levels as in transgenic mice with 
overexpression of human low density lipoprotein receptors which accelerate the 
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the clearance of Lp(a), Lp(a) levels are low (Hofinann et al” 1990). In subjects 
with familial hypercholesterolemia, who tend to elevated Lp(a) concentrations, 
there is defective LDL receptor function (Utermaim, 1989). Therefore, factors 
affecting LDL receptor expression may have an effect on plasma Lp(a) 
concentrations. Estrogens are known to increase LDL-receptor activity (Seed, 
1991). It is possible that estrogens in men affect LDL-receptor activity, reducing 
both apoB (LDL) and Lp(a) levels. It seems that the association between Lp(a) 
and LDL partly due to apoB may be through LDL receptor mediated by 
unconjugated E2. As nicotinic acid is believed to have its effect on LDL levels 
by reducing VLDL synthesis it may lower Lp(a) (Gurakar et aL, 1985;, Carlson 
et al” 1989; Schmidt et al” 1993) by a similar mechanism. That may imply that 
lowering Lp(a) concentration occurs by reducing synthesis rather than by 
increasing its catabolism. The mechanism is thought to be by decreasing LDL 
production. There have been no suggestions to knowledge of estrogens reducing 
VLDL production. I f these were shown to be in association with Lp(a), as for 
apoB, it might be exerting its effect on catabolism which might be regulated by 
serum unbound E2. Recently fish oil has been noted to have the ability to lower 
Lp(a) level as well (Scanu and Fless, 1990; Fu et al” 1991) although effects on 
LDL are not consistent or marked. On the other hand, HDL3 level is also 
reduced by nicotinic acid (Blum et al, 1977; Shepherd et aL, 1979) and fish oil 
(Mori et aL, 1991). It was suggested that the effect of nicotinic acid on the HDL 
subfraction distmbution may be mediated via the net transfer of apoA-I from 
HDL3 to HDL2 and/or via the reduction in apoA-II synthesis (Shepherd et al” 
1979). 
In view of the effect of nicotinic acid and fish oil on Lp(a) and HDL3 of 
which both have direct associations with urinary unconjugated E2 excretion rate, 
(for Lp(a) at least parametrically, Pearson's r=0.36618 p=0.0123), it may be 
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that both HDL3 and Lp(a) are affected by some common hormonal factors. 
Moreover, in pathological states, such as diabetes, nephrotic syndromes 
and end-stage kidney disease, Lp(a) (Kapelrud, et al” 1991; Jenkins et al” 1991; 
Takegoshi et al” 1990; Dieplinger et al” 1993) and HDL3 (Muls et al” 1985; 
Short et oL, 1986) levels in serum are often found to be elevated. There has been 
a report of a decrease in serum apo(a) in patients after renal transplantation. This 
suggests that abnormal renal function affects Lp(a) metabolism (Black and 
Wilcken, 1992), although the mechanism is still unknown (Keane et al” 1992). 
V.4. Testosterone, and HDL-C and its subfractions 
The association between total serum- and free-testosterone and total HDL-
C reduces after adjustment for age, BMI, W/H ratio, SHBG and triglycerides, 
and the level of HDL is strongly inversely correlated with that of triglyceride in 
plasma (cf. Table IV,5.A & Table IV.5.B). An understanding of HDL-
cholesterol is also complicated by the existence of the major subfractions HDL〗-
C and HDL3-C, and their interactions. Variation in total HDL is largely caused 
by changes in HDL2 and the amount of HDL3 in the blood of normal men is 
relatively constant (Anderson et al, 1978; Wood and Haskell, 1979). Therefore 
it is expected that total HDL-C and HDL2-C are strongly correlated univariately 
(r=0.86426, pCO.OOOl). It is interesting that HDL-C and HDL3-C are also 
strongly correlated (r=0.71815, p<0.0001), and also as shown in this study 
(Tables IV.5.A & rVMD)，the HDL2-C subfraction has an association with 
testosterone, and HDL3-C with estradiol. I f HDL2-C is the strongest predictor 
of both the presence and the extent of CAD as suggested in angiographic studies 
(Miller et al” 1981, 1987; Drexel et al” 1992) then an understanding of the 
association with testosterone levels may be important, because the association 
between total- and free- testosterone and HDL2-C persists even after adjustment 




and apoE which are involved in the metabolism of triglyceride-rich lipoprotein. 
This is demonstrated by the inverse correlation between HDL2 and triglyceride in 
univariate correlation (Anderson, 1978; Patsch et al” 1983, 1987). HDL3-C was 
associated with apoA-I and apoA-II as shown both in humans (Blum et al, 1977, 
Shepherd et al” 1979) and in transgenic mice (Schultz et al” 1992). To produce 
HDL3 particles from HDL2 it is necessary to remove about two-thirds of the 
cholesteryl ester molecules from the HDL2 (Eisenberg, 1986) which is regulated 
by the enzyme, hepatic lipase (HL), and an appropriate amount of surface 
molecules from triglyceride-rich lipoproteins regulated by lipoprotein lipase 
(LPL) (Taskinen & Nikkila，1981; Silverman et al” 1993). After multiple linear 
regression (Table IV.5.A & Table IV.5.B), since HDL3 is strongly positively 
correlated with the urinary unconjugated E2 (^=+2.8, p=0.0076) and HDL2 is 
positively correlated with serum total and unbound testosterone ( ,= +2.60， 
/?=0.0128; t= +2.94, 77=0.0052，respectively), the H L and/or LPL could 
possibly be under the control of unbound testosterone and/or E2 in plasma. It 
should be noted that women have higher LPL activities than men. However, 
reduced LPL activity and enhanced HL activity leads to a reduction of total HDL 
due to decreased level of HDL2 (Seed, 1991). 
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Chapter VI . Conclusions 
Recently focus on the influence of the menopause on serum lipoprotein-
lipids in healthy women has suggested that the association of menopause with 
potentially adverse changes in lipoprotein-lipids is independent of any effects of 
ageing but due either directly or indirectly to estrogen deficiency (Jensen et al.， 
1990; Stevenson et al” 1993). Postmenopausal women have significantly higher 
concentrations of total cholesterol, LDL-C and HDL3-C which are thought to be 
correlated with the reduction of estrogen production in the ovaries. In 
postmenopausal women, the reduction of estrogen levels, as compared to 
premenopausal women, has been shown to be associated with a pattern of 
lipoprotein-lipids profiles similar to that in men. After the menopause females 
and males have a similar risk for coronary heart disease. This study suggests that 
estradiol secretion may contribute to variation in lipoprotein-lipids in men. Since 
most of the estradiol in men originates from the transformation of testosterone, it 
is possible that there is a complex interaction between estradiol and testosterone 
as far as serum lipoprotein-lipids are concerned. 
The unique feature of this study was the measurement of the urinary 
excretion rates of testosterone and estradiol. The measurement of 24-hour urinary 
excretion of sex hormones seemed likely to be more useful than that of plasma 
hormones because the urinary excretion rate of a hormone is expected to be a 
better index of its production or secretion rate, and the urinary excretion rate of 
unconjugated hormone might be a closer reflection of circulating biologically 
active hormone. In this study it is demonstrated that the secretion and production 
of estradiol, rather than that of testosterone, is inversely associated with the 
plasma concentrations of cholesterol, triglyceride, LDL-C, and apoB, and 
directly associated with those of HDL3 and possibly Lp(a). It is unlikely these 
associations were due to the potential confounders BMI, SHBG, and triglyceride 
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because the association remained significant on stepwise multiple linear 
regression. The effect of E2 on LDL-C concentrations is probably mediated 
through LDL-receptors. The effect on triglyceride concentrations may be 
mediated through E2 effects on lipoprotein lipase, as estradiol increases the 
activities of LDL-receptors and lipoprotein lipase (Godsland et al” 1987; Seed, 
1991). The protection afforded to post-menopausal women on HRT (Knopp, 
1988; Barrett-Connor and Bush, 1991) may also be partly mediated by 
antithrombotic effects on the arterial wall (Adams et al” 1990). However, other 
reports have suggested that men with CAD actually have higher estrogen levels 
than men without disease (Phi l l ips^1993) implying that any beneficial effect on 
lipoproteins in men from higher estrogen levels provides no protection. It must 
be admitted, at this point, that the existence of correlations is not proof of 
metabolic cause and effect. Further studies in this area should be pursued for 
these might be helpful in the elucidation of the relation between sex hormone 
secretion in normal and abnormal lipid states. Lp(a) and HDL3-C levels are both 
high in nephropathy (Keane et al., 1990, 1992). Perhaps disturbance in sex-
hormone levels should be considered as possible contributions. 
HDL-cholesterol, including its subfraction HDL2-C is associated with 
testosterone secretion and production. In this regard, the present results in 46 
Chinese male subjects show that the serum testosterone persistently has a direct 
correlation with HDL-C and/or HDL2-C, which is in agreement with Heller et 
al (1983)，Lichtenstein et al. (1987), and Barrett-Conner and Khaw (1988)，but 
not with the previous studies of Semmens et al( 1983), Goldberg et al (1985), 
and Stefanick et al (1987). As HDL2 is metabolically linked with triglyceride-
rich lipoproteins (Patsch et al, 1983，1987，1992; Silverman et al., 1993) the 
association between testosterone in men and postprandial lipemia (or the 




In summary, the above findings suggest that sex hormones have effects on 
lipoprotein-lipids concentrations in serum and may therefore play a role in the 
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Appendix i： Parameter listing for cholesterol and triglyceride assayed 
by Cobas Bio automatic analyser 
1. Units mmol/L 
2. Calculation factor 0 
T S t a n d a r d 1 concentration 8.68 (for cholesterol), 3.26 for trig. 0.54 f o r ~ 
HDL 
4. Standard 2 concentration 4.34 (for cholesterol), 1.63 for trig. 1.08 for 
HDL 
~5.Stamdard 3 concentration 0 (for cholesterol and triglyceride), 2.17 for 
HDL 
6. Limit — 18 
7. Temperature (Degree. C) 37 
8. Type of analysis 5 
9. Wavelength (NM) — 520 
10. Sample volume " 1 |LI1 (for cholesterol and trig.)，20 \i\ for HDL 
11. Diluent volume [i\ (for cholesterol and trig.)，60 \i\ for HDL 
12. Reagent volume 300 |LI1 
13. Incubation time 0 
14. Start reagent 0 
15. Time of first reading 5 second 
16. Time interval 300 second 
17. Nnumber of readings 2 
18. Blanking mode 1 
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Appendix ii, b.—Association of age and serum albumin and yGT 
r=0.41128 
p=0.0045 
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Appendix il c.— Correlation of age，BMI and serum lipoprotein-lipids 
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Appendix it d- Association of Age, BMI, WHR, GGT, SHBG, and serum 
testosterone, 
r=0.4118 r=0.29348 
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Appendix il e,-'Correlation of serum cholesterol and lipoprotein-lipids and 
apolipoprotein. 
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Appendix il /.—Association of urinary non-conjugated E2 to lipoprotein-
lipids, serum E】and urinary total E2 
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Appendix iig.-Correlation of urinary total & non-conjugated testosterone 
and sex hormone in serum and urine and urinary free Cortisol 
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Appendix ii lu—Correlation of serum yGT and lipoprotein-lipids and 
apolipoprotein 
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Appendix il L 一 Correlation of HDL-C and other lipoprotein-lipids and 
SHBG 
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Appendix il k—Correlation of LDL-C and HDL subfractions, Lp(a) and 
apoB 
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Appendix il l—Correlation of the ratio of urinary free & urinary total 
estradiol (fuE2/tuE2) and lipoprotein-lipids 
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Appendix ii nt—Correlation of serum estradiol and lipoprotein-lipids 
6 8 
I C _ p-0.053 _ 〇 7 — • • p=0.0504 -
\ 3 - • • - E • 
O , •• • — E 6 - • •/• -
目 • - o 5 • 
3 2 - •• ！ 3 — •• ••••• • -
1 I _ _ ^ I o 2 ‘ 1 ‘ 
50 100 150 200 250 50 100 150 200 250 
1.2 4.0 n 
r=0.29778 _ > -7 c. _ r=-0.35327_ 
_J 1 n _P=0.0444 — O vJ.O - • p=0.016 — 
\ • • E 3.0 - . • -
！ 0.8 - • • • - E 2.5 _ • • • -
E 0.6 — ••• ， • — 召 2.0 - -
^ 0 4 - - \ ！ 0 ：. ： 
工 0 . 2 — •*••:•••••• — ^ 0 . 5 - ••‘‘ -
0.0——‘——‘——L—— ^ 0 . 0 — — ‘ — — ‘ — — I — — 
50 100 150 200 250 50 100 150 200 250 
Serum E2 pmo l / L Serum E2 p m o l / L 
126 
App. ii. p. 
124 
Appendix il fL-Correlation of SHBG and lipoprotein-lipids and 
apolipoprotein 
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Appendix ii. o.—Correlation of serum total testosterone and lipoprotein-
lipids, apolipoprotein and SHBG 
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Appendix il p,—Correlation of triglyceride and lipoprotein-lipids and 
apolipoprotein 
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Appendix il q.—Correlation of urinary total estradiol and lipoprotein-lipids 
and apoB 
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